

B3

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 August 2001 (02.08.2001)

PCT

(10) International Publication Number
WO 01/55103 A2

(51) International Patent Classification⁷: C07D
(21) International Application Number: PCT/US01/02804
(22) International Filing Date: 29 January 2001 (29.01.2001)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
60/178,652 28 January 2000 (28.01.2000) US
(71) Applicant: NEUROGEN CORPORATION [US/US]; 35
Northeast Industrial Road, Branford, CT 06505 (US).

(72) Inventors: BENNETT, Michele; 35 NE Industrial Road,
Branford, CT 06505 (US). BRODBECK, Robbin; 35 NE
Industrial Road, Branford, CT 06505 (US). KRAUSE,
James; 35 NE Industrial Road, Branford, CT 06505 (US).

(74) Agents: RICHARDS, John; Ladas & Parry, 26 West 61st
Street, New York, NY 10023 et al. (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: CHIMERIC NEUROPEPTIDE Y RECEPTORS



(57) Abstract: Novel chimeric G-protein coupled receptors are provided as isolated polypeptides, membrane preparations contain-
ing such chimeric receptors, nucleic acids encoding such chimeric receptors, and cells expressing such receptors. The chimeric
receptors are NPY5 receptors with most or all of either one or both of the third cytoplasmic loop domain or the C-terminal intracel-
lular domain of NPY5 replaced with the corresponding region(s) of another NPY receptor, preferably an NPY1 receptor.

WO 01/55103 A2

- 1 -

CHIMERIC NEUROPEPTIDE Y RECEPTORSBACKGROUND OF THE INVENTION

G protein-coupled receptors (GPC's): GPC's are a class membrane-spanning proteins that act to transduce signals into the cell in response to stimulation by hormones, neurotransmitters, and other extracellular signaling molecules, including peptides and smaller organic molecules. See, e.g., Gather, et al., *J. Biol. Chem.*, 273:17979-82, and 1998. Receptor polypeptides such as GPC's are typically found at very low concentrations on the cell surface. Because of their key roles in mediating cellular responses, GPC's are highly effective targets for drug action. Isolated GPC's, particularly as components of isolated membrane preparations, as well as cloned GPCR genes (preferably cDNAs) and cells expressing such genes, are used in the pharmaceutical industry as the basis of drug discovery and development assays. Means to obtain artificially high concentrations of GPC's in cells and membranes are much sought after, as high levels of active receptors facilitate assays with higher sensitivity.

GPC's consist of a single contiguous amino acid chain comprising seven hydrophobic domains interconnecting eight hydrophilic domains. Once the amino acid sequence of a GPCR is determined, the precise locations of these domains may be conveniently calculated by computer analysis of hydrophobicity or hydrophilicity using hydropathy profiles, such as standard Kyte-Doolittle analysis (Kyte and Doolittle, *J. Mol. Biol.* 157:105-32, 1982). The transition boundaries between the hydrophobic and hydrophilic domains are typically marked by the presence of charged or polar (hydrophilic) amino acid residues at the beginning or end of a stretch of uncharged and nonpolar (hydrophobic) residues. The N-terminus of a cell surface GPCR extends into the extracellular space and the C-terminus into the cytoplasm of the cell. Each of the seven hydrophobic domains is about 20-25 amino acids long, assumes a largely alpha helical conformation, and crosses once through the plasma membrane, its entire extent generally embedded in the membrane. The hydrophobic domains of GPCRs are thus also referred to as transmembrane (TM) domains, membrane-spanning alpha helical domains, or the like, while the hydrophilic domains are referred to as either extracellular or intracellular domains, depending upon their predicted locations in a functional, membrane-bound GPCR. The hydrophilic domains interconnecting TM domains form

- 2 -

loops within the cytoplasm or extracellular space, and are consequently referred to as cytoplasmic or extracellular loop domains.

GPCRs have been structurally modeled as to secondary and tertiary structural conformation, and the precise locations of the extracellular, TM and intracellular domains within their primary structures (i.e., their amino acid sequences) are well known and generally agreed to in the art (see, e.g., Baldwin, *EMBO J.* 12:1693-703, 1993, also see <http://swift.embl-heidelberg.de/7tm/seq/snakes.html>). These receptor proteins thus comprise an extracellular N-terminal domain, seven membrane-spanning alpha helical domains (connected by three intracellular loop domains alternating with three extracellular loop domains), and an intracellular C-terminal domain.

The locations of the various domains of neuropeptide Y (NPY) receptors can be readily determined by inspections of the "Viseur's snake like view" for the particular receptor polypeptide generated by the European Molecular Biology Laboratory's Viseur software. These Viseur's snake like views are electronically published for a wide variety of GPCR polypeptides (including NPY receptors of various mammalian and non-mammalian vertebrate species --<http://swift.embl-heidelberg.de/7tm/seq/snakes.html>). In these snake like views, the amino acids of the polypeptide sequence of the receptors are set forth as one-letter-code-containing circles. The TM domains are depicted as diagonally stacked circles to represent the alpha helical conformation believed to be adopted by of these domains in situ, while the other domains are depicted as vertically and horizontally arrayed sequences.

The precise structural characteristics (importantly including and largely flowing from the primary structure) of the extracellular and membrane spanning domains are believed to largely determine the ligand specificity of the receptor. In particular, peptide binding typically involves amino acid residues near the top of a plurality of the seven TM domains (i.e., TM domain residues adjacent to, generally within about ten to fifteen amino acids from, the extracellular domains) and within the extracellular domains of the receptors, while non-peptide type ligands are believed to typically bind deeper in the plane of the membrane, between several of the TM domains.

The precise structures of its third intracellular loop and intracellular C-terminal domain are believed to dictate important functional characteristics of GPCRs. In particular, they are believed to significantly contribute to the determination of the

- 3 -

characteristics of the specific G-protein binding interactions of any particular GPCR, including any of the various neuropeptide Y (NPY) receptors, with any of the many subtypes of heterotrimeric G-proteins. As these subtypes are often functionally distinct, these changes in binding interactions are believed to result in alterations in receptor
5 function. These domain structures are, of course, a function of the amino acid (primary) sequence of each domain.

Without wishing to be bound by any particular theory of operation, it is believed that these specific binding interactions are involved in bringing the G-protein into close proximity with the receptor's other intracellular domains (the three intracellular loops
10 connecting six of the seven TM alpha helices), an action that is believed to be fundamental to determining the receptor's signal transduction functionality. Both the third intracellular loop and the C-terminal domain thus play key roles in determining the type of intracellular signal that is transmitted by a GPCR upon activation.

Signal transduction is initiated by the binding of an agonist ligand to the receptor.
15 This elicits conformational changes in the extracellular domains. When the receptor is functioning properly, these conformational changes propagate through the TM domains and result in a coordinated change in the intracellular portions of the GPCR. This precise alteration in the intracellular domains acts to trigger the associated G-protein complex to modulate intracellular signaling. In particular, in an NPY receptor, the alteration triggers
20 a GTP for GDP exchange on the G alpha subunit of the complex, the release of the G-protein complex from the receptor, and the dissociation of the G alpha from the G beta and G gamma subunits of the complex. The ultimate result of these alterations is the activation or inhibition of intracellular signaling systems.

Chimeric GPCRs: In the course of analyzing the specific contributions of the
25 various GPCR domains to receptor function, many different chimeric GPCR molecules with heterologous N-terminal and C-terminal domains have been constructed using recombinant DNA techniques. These efforts have yielded unpredictable results, depending upon the sources of the various domains being combined in a chimeric receptor. See, e.g., Blount, et al., *J. Biol. Chem.*, 268:16388-95, 1993; Liggett, et al.,
30 *Proc. Natl. Acad. Sci. USA*, 90: 3665-69, 1993.

In some cases, attempts to express chimeric GPCR-encoding cDNAs (comprising certain combinations of DNA fragments encoding heterologous domains) result in a

- 4 -

receptor that is poorly expressed at the cell surface. In other cases, the expressed chimeric receptors localize into different membranes than do native receptors. See, e.g., Moyle, et al., *J. Biol. Chem.*, 266:10807-12, 1991; and Mery and Boulay, *J. Biol. Chem.*, 269:3457-63, 1994.

- 5 Sometimes, in spite of proper membrane insertion, the combined heterologous domains do not function properly. Often the conformational changes in the extracellular domains triggered by the binding of an agonist ligand is not adequately propagated to the intracellular portions of the receptor, and thus fails to trigger the activation of the associated G protein to generate a sufficient modulation of intracellular signaling.
- 10 Chimeric receptors may also exhibit altered ligand-binding specificity as compared to the native receptor from which the ligand-binding portion of the chimeric receptor has been obtained. See, e.g., Blount, et al., *J. Biol. Chem.*, 268:16388-95, 1993; and Buggy, et al., *J. Biol. Chem.*, 270:7474-78, 1995.

- Native GPCRs transduce a cell surface agonist-binding event into an intracellular
15 signal via the intervening actions of cytosolic heterotrimeric G-protein complexes. There is a growing list of heterotrimeric G-protein combinations demonstrated to couple to GPCRs. The G-protein complexes in turn activate specific effector proteins that continue the signal transduction process, typically by generating a second messenger such as cAMP, cGMP, inositol 1,4,5-bisphosphate or arachidonic acid. In normal GPCR
20 function, a specific G-protein alpha beta and gamma subunit combination typically activates a specific effector protein, although some GPCRs have been shown to couple to multiple signal transduction pathways.

- Assays of GPCR Function: Assays allowing for the sensitive and accurate determination of GPCR function are much sought after, as they are useful research tools,
25 e.g., for analyzing the effects of compounds that modulate GPCR function and thereby can act as drugs. For example, agonist-induced GTP γ ³⁵S binding by GPCRs provides a functional measure of G-protein activation. Although some receptors may not provide optimal results in such assays, this type of assay has been widely used for many GPCRs. It is used, e.g., to distinguish agonists from antagonists and to determine the potency and
30 efficacy of agonists for a given GPCR (see, e.g., Thomas et al., *J. Recept Signal Transduct Res* 15:199-211, 1995).

- 5 -

Robust functional activity assays are as yet available to measure only a limited subset of G-protein-mediated signaling pathways. Robust assays are those that can consistently provide signal-to-noise characteristics allowing for the acquisition of statistically significant data sets from quadruplicate, more preferably triplicate, and most preferably from duplicate sample runs. In all GPCR research, and particularly in the area of drug discovery, such robust assays facilitate the acquisition of useful and informative data.

The robustness of such an assay is dramatically influenced by the particular receptor used in the assay. Thus, GPCRs with signaling characteristics adapted so as to facilitate robust functional activity assays are particularly valuable research tools.

NPY and NPY Receptors: Neuropeptide Y (NPY) consists of 36 amino acids and is one of the most abundant peptides present in the mammalian central and peripheral nervous systems. NPY exhibits a variety of potent central and peripheral effects including modulation of feeding, memory, blood pressure, cardiac contractility, and intestinal secretion. Classical pharmacological evidence suggests that NPY effects are mediated by a number of different GPCR subtypes. Y1, Y2, Y4, Y5, Y6 and Y7 receptors (alternatively referred to as NPY1, NPY2, NPY4, NPY5, NPY6, and NPY7 receptors) have all been cloned and recombinantly expressed. All known NPY receptors are G-protein-coupled transmembrane proteins with seven membrane spanning TM domains.

The best characterized of the NPY receptors is Y1, which has been cloned from the mouse (Eva, et al., *FEBS Lett.* 314:285, 1992), rat (Eva, et al., *FEBS Lett.* 271:80, 1990), and human (Larhammar, et al., *J. Biol. Chem.* 267:10935, 1992). It is considered to be postsynaptic and to mediate most of the peripheral actions of NPY, including vasoconstriction and increased arterial blood pressure (Larhammar, et al., *J. Biol. Chem.* 267:10935, 1992; Westfall, et al., *Ann. NY Acad. Sci.* 611:145, 1990). The Y1 receptor in the central nervous system has been associated with various effects of NPY, including its anxiolytic action, its effects on feeding behavior, and its reduction of spontaneous locomotor activity (see, e.g., Wahlestedt, et al., *Science* 259:528, 1993).

The NPY5 receptor has been suggested to play a key role in the modulation of feeding behavior. Studies of seizure-prone mice have led to the suggestion that the Y5 receptor may also have an anti-epileptic activity in the control of limbic seizures. Y5-like

receptors have also been implicated in attenuation of morphine withdrawal symptoms, enhancement of diuresis and natriuresis, lowering of blood glucose, inhibition of luteinizing hormone secretion, and reduction of acetylcholine release in the ileum. See, for example, Hu, et al., *J. Biol. Chem.*, 271:26315-19, 1996; Gerald, et al., *Nature*, 382:168-71, 1996; Blomqvist, et al., *TINS*, 20: 294-98, 1997. The sequences of Y1 and Y5 receptors of humans, dogs, mice, guinea pigs, rats, and Y1 receptors of sheep have all been reported and have been published, e.g., by Genbank (<http://www.ncbi.nlm.nih.gov/>).

Y1 receptors are structurally characterized as having a single polypeptide chain comprising, in N-terminal to C-terminal order, an NPY1 N-terminal extracellular domain, an NPY1 first TM domain, an NPY1 first intracellular loop domain, an NPY1 second TM domain, an NPY1 first extracellular loop domain, an NPY1 third TM domain, an NPY1 second intracellular loop domain, an NPY1 fourth TM domain, an NPY1 second extracellular loop domain, an NPY1 fifth TM domain, an NPY1 third intracellular loop domain, an NPY1 sixth TM domain, an NPY1 third extracellular loop domain, an NPY1 seventh TM domain, and an NPY1 C-terminal intracellular domain.

Y5 receptors are structurally characterized as having a single polypeptide chain comprising, in N-terminal to C-terminal order, an NPY5 N-terminal extracellular domain, an NPY5 first TM domain, an NPY5 first intracellular loop domain, an NPY5 second TM domain, an NPY5 first extracellular loop domain, an NPY5 third TM domain, an NPY5 second intracellular loop domain, an NPY5 fourth TM domain, an NPY5 second extracellular loop domain, an NPY5 fifth TM domain, an NPY5 third intracellular loop domain, an NPY5 sixth TM domain, an NPY5 third extracellular loop domain, an NPY5 seventh TM domain, and an NPY5 C-terminal intracellular domain.

In the human Y1 receptor (DNA sequence - SEQ ID NO:1, amino acid sequence - SEQ ID NO:2), the third intracellular loop domain consists essentially of amino acids 232 (Phe) to 263 (Ile) of SEQ ID NO:2, as indicated, for example, by the Visser's snake like view for this receptor (see, e.g., http://swift.embl-heidelberg.de/7tm/seq/vis/NY1R_HUMAN/NY1R_HUMAN.html). In accordance with the amino acid sequence residue charge/polarity considerations discussed above, the termini of this loop are preferably defined by the presence (within the domain) of a charged residue (Lys 233 of SEQ ID NO:2) located at the end of the long stretch of hydrophobic residues (the fifth TM

- 7 -

domain) and a charged residue (Arg 260 of SEQ ID NO:2) located at the beginning of the long stretch of hydrophobic residues (the sixth TM domain).

In the rat Y1 receptor, the third intracellular loop domain consists essentially of amino acids 231 (Phe) to 262 (Val) of SEQ ID NO:3, as indicated, for example, by the
5 Viseur's snake like view for this receptor (see, e.g., http://swift.embl-heidelberg.de/7tm/seq/vis/NY1R_RAT/NY1R_RAT.html). In accordance with the amino acid sequence residue charge/polarity considerations discussed above, the termini of this loop domain are preferably defined by the presence (within the domain) of a charged residue (Lys 232 of SEQ ID NO:3) located at the end of the long stretch of hydrophobic residues
10 (the fifth TM domain) and another charged residue (Arg 259 of SEQ ID NO:3) located at the beginning of the long stretch of hydrophobic residues (the sixth TM domain).

The following discussion of human NPY5 domains illustrates the domain structure information available electronically for this receptor (see, e.g., http://swift.embl-heidelberg.de/7tm/seq/vis/NY5R_HUMAN/NY5R_HUMAN.html).

15 In accordance with this information: A preferred Y5 N-terminal extracellular domain consists essentially of residues 1 (Met) to 50 (Leu) of SEQ ID NO:13. A preferred Y5 first TM domain consists essentially of residues 51 (Gln) to 71 (Leu) of SEQ ID NO:13. A preferred Y5 first intracellular loop domain consists essentially of residues 72 (Ile) to 84 (Thr) of SEQ ID NO:13. A preferred Y5 second TM domain
20 consists essentially of residues 85 (Thr) to 105 (Ser) of SEQ ID NO:13. A preferred Y5 first extracellular loop domain consists essentially of residues 106 (Pro) to 125 (His) of SEQ ID NO:13. A preferred Y5 third TM domain consists essentially of residues 126 (Ile) to 146 (Ala) of SEQ ID NO:13. A preferred Y5 second intracellular loop domain consists essentially of residues 147 (Ile) to 167 (Tyr) of SEQ ID NO:13. A preferred Y5
25 fourth TM domain consists essentially of residues 168 (Phe) to 188 (His) of SEQ ID NO:13. A preferred Y5 second extracellular loop domain consists essentially of residues 188 (Ser) to 220 (Ala) of SEQ ID NO:13. A preferred Y5 fifth TM domain consists essentially of residues 221 (Phe) to 241 (His) of SEQ ID NO:13. A preferred Y5 third intracellular loop domain consists essentially of residues 242 (Thr) to 378 (Tyr) of SEQ
30 ID NO:13. A preferred Y5 sixth TM domain consists essentially of residues 379 (Arg) to 401 (Thr) of SEQ ID NO:13. A preferred Y5 third extracellular loop domain consists essentially of residues 402 (Arg) to 414 (Lys) of SEQ ID NO:13. A preferred Y5 seventh

- 8 -

TM domain consists essentially of residues 415 (Leu) to 438 (Leu) of SEQ ID NO:13. A preferred Y5 C-terminal intracellular domain consists essentially of residues 439 (Asn) to 455 (Met) of SEQ ID NO:13.

5 The following discussion of human NPY1 domains illustrates the domain structure information available electronically for this receptor (see, e.g., http://swift.embl-heidelberg.de/7tm/seq/vis/NY1R_HUMAN/NY1R_HUMAN.html). This Visueur's snake like view also indicates numerous points at which variant sequences for human NPY1 have been found or have been created.

10 In accordance with this information: A preferred Y1 fifth TM domain consists essentially of residues 211 (Tyr) to 231 (Tyr) of SEQ ID NO:2. A preferred Y1 third intracellular loop domain consists essentially of residues 232 (Phe) to 263 (Ile) of SEQ ID NO:2. A preferred Y1 sixth TM domain consists essentially of residues 264 (Met) to 286 (Phe) of SEQ ID NO:2. A preferred Y1 seventh TM domain consists essentially of residues 300 (Leu) to 323 (Leu) of SEQ ID NO:2. A preferred Y1 C-terminal
15 intracellular domain consists essentially of residues 324 (Asn) to 384 (Ile) of SEQ ID NO:2.

Further discussions of NPY, GPCR, and NPY-receptor structure, physiology, and pharmacology (including NPY-receptor and other GPCR domain structure and nomenclature) are presented in US Patent No. 6,001,970, issued on Dec. 14, 1999 in the
20 names of Margaret A. Cascieri, Douglas John MacNeil, and Catherine D. Strader, which is incorporated herein by reference for its teachings in such regard at columns 1-5, 6 (lines 1-12, 30-45, and 64-67) 7-8, and 9 (lines 1-35) and Figures 1-3.

Further discussions of Y1 and Y5 receptors are presented in US Patent No. 5571695 issued Nov. 5, 1996, in the names of Lisa Selbie, Herbert Herzog, and John
25 Shine; US Patent No. 5,965,392, issued Oct. 12, 1999, in the names of Yinghe Hu, Michael L. McCaleb, Brian T. Bloomquist, Jaime R. Flores-Riveros, and Linda J Cornfield; US Patent No. 5,968,819, issued Oct. 19, 1999 in the names of Christophe P.G. Gerald, Richard L. Weinshank, Mary W. Walker, and Theresa Branchek; and in US Patent No. 5,985,616, issued Nov. 16, 1999 in the names of Eric McFee Parker, Catherine
30 Devine Strader, and Mark Stephen Rudinski, each of which is incorporated herein by reference for its teachings in regard to NPY receptor structure and function.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Chimeric NPY receptors exhibit altered functional G-protein coupling characteristics -- G-protein alpha subunit rank order of ligand-induced responses. Data is expressed as % maximal response and was derived by determining the maximal agonist stimulated % above basal stimulation for each receptor type, and normalizing all other data within that receptor type to the maximal (100%) value. The indicated NPY expression vector constructs were those directing the expression of the Y1 receptor cDNA of SEQ. ID. NO:1 (filled bars), the Y5 receptor DNA of SEQ. ID. NO:4 (open bars), the chimeric NPY5ΔY1CT receptor cDNA of SEQ. ID. NO:7 (vertical stripes), or the chimeric NPY5ΔY1IC3 receptor cDNA of SEQ. ID. NO:5 (horizontal stripes).

DESCRIPTION OF THE SEQUENCE LISTINGS

SEQ ID NO:1. Human Y1 receptor DNA sequence.

SEQ ID NO:2. Human Y1 receptor amino acid sequence.

SEQ ID NO:3. Rat Y1 receptor amino acid sequence.

SEQ ID NO:4. Human Y5 receptor DNA sequence.

SEQ ID NO:5. Human NPY5ΔY1IC3 chimera DNA sequence.

SEQ ID NO:6. Human NPY5ΔY1IC3 chimera amino acid sequence.

SEQ ID NO:7. Human NPY5ΔY1CT chimera DNA sequence.

SEQ ID NO:8. Human NPY5ΔY1IC3/ΔY1CT chimera DNA sequence.

SEQ ID NO:9. Human NPY5ΔY1CT chimera amino acid sequence.

SEQ ID NO:10. Human NPY5ΔY1IC3/ΔY1CT chimera amino acid sequence.

SEQ ID NO:11. Amino acid sequence of the His_{6x} epitope.

SEQ ID NO:12. Amino acid sequence of the FLAG epitope.

SEQ ID NO:13. Human Y5 receptor amino acid sequence.

SEQ ID NO:14. 5' Y5 primer.

SEQ ID NO:15. 3' Y5 primer.

SEQ ID NO:16. HY1L3S sense oligo.

SEQ ID NO:17. HY1L3AS anti-sense oligo.

SEQ ID NO:18. HY1R1 forward primer (creates EcoR1 site).

SEQ ID NO:19. HY5R1 reverse primer (creates EcoR1 site).

SEQ ID NO:20. Dog NPY5ΔY1IC3 chimera.

- 10 -

SEQ ID NO:21. Dog NPY5ΔY1IC3/ΔY1CT chimera.

SEQ ID NO:22. Mouse NPY5ΔY1CT chimera.

SEQ ID NO:23. Rat NPY5ΔY1IC3 chimera.

SEQ ID NO:24. Rat NPY5ΔY1CT chimera.

5 SEQ ID NO:25. Rat NPY5ΔY1IC3/ Y1CT chimera.

SEQ ID NO:26. Pig NPY5ΔY1IC3 chimera.

SEQ ID NO:27. Pig NPY5ΔY1IC3/ΔY1CT chimera.

SEQ ID NO:28. NPY5 forward primer hY5-45F.

SEQ ID NO:29. NPY5 reverse primer hY5-1450R.

10 SEQ ID NO:30. African Green Monkey NPY5 DNA sequence.

SEQ ID NO:31. African Green Monkey NPY5 amino acid sequence.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide novel chimeric NPY receptors.

Preferably these receptors display the ligand binding pharmacological characteristics

15 typical of Y5 receptors while mediating signal transduction effects typical of Y1 receptors (preferably involving G-protein coupling typical of Y1 receptors). It is an additional object to provide cells expressing such chimeric NPY receptors. Preferably these chimeric receptor-expressing cells provide a source of chimeric receptors (typically in the form of the cells themselves or in the form of isolated membrane preparations) that are

20 adapted for use in robust assays of either or both of receptor binding and receptor function (e.g., receptor G-protein subunit binding or receptor signal transduction). Particularly preferred receptors can be expressed at higher levels than native (non-chimeric, non-mutant) Y5 receptors, and particularly preferred cells express such receptors at such higher levels.

25 It is a further object of the invention to provide assays for identifying compounds that specifically bind to NPY5 receptors. Such assays comprise contacting a compound to be tested with cells or isolated membranes of the invention and detecting the binding of the compounds to the cells.

30 The invention also deals with a method of treating a condition in a subject where the condition is, for example, an eating disorder, a seizure disorder, a blood pressure disorder, a locomotor disorder or an anxiety disorder. The method includes administering

- 11 -

to the subject an effective amount of a composition comprising a compound identified by the aforementioned assays.

To these ends, this invention first provides chimeric NPY receptor proteins comprising a recipient NPY5 receptor comprising at least one domain substitution wherein the substitution comprises the replacement of one or both of the third intracellular loop domain and the C-terminal intracellular domain. The substituted donor domains are derived from a different type of NPY receptor (e.g., a Y1 receptor, a Y2 receptor, or a Y4 receptor, the "donor receptor") than the recipient NPY5 receptor. Each donor NPY receptor preferably comes from the same class of animal, preferably from the same order of animal, more preferably from the same family of animal, yet more preferably from the same genus of animal, and most preferably from the same species of animal as the recipient NPY5 receptor is obtained from. Where at least two domains are substituted, each substituted donor domain may be obtained from the same or a different species of animal as the other, preferably all are from the same species of animal and from the same type of donor NPY receptor.

In this embodiment, each fragment of a substituted recipient domain of the recipient Y5 receptor is an intracellular domain consisting essentially of a contiguous length of at least about 50% the length of the entire recipient Y5 receptor domain in which the substitution is being made. In this embodiment, this NPY5 fragment is deleted and replaced by a corresponding fragment, i.e., one with termini located at about the same number of amino acid residues (e.g., within plus or minus 10%, preferably within plus or minus 5%, most preferably within plus or minus 2% of the number of amino acid residues in the entire corresponding donor domain) from the adjacent end of each adjacent donor NPY receptor TM domain (e.g., the fifth and sixth TM domains or the seventh TM domain) as each terminus of the deleted and replaced (recipient) fragment of the recipient Y5 receptor is located from its nearest (adjacent) recipient NPY5 receptor TM domain. Preferably the resulting domain of the chimeric receptor has 1) the same number of amino acids as the corresponding donor NPY receptor domain or 2) the same number of amino acids as the corresponding recipient NPY5 receptor domain, or, 3) a number of amino acids intermediate between 1) and 2). Such domain fragments may have each terminus (independently from any other terminus) located within an adjacent TM domain (except,

- 12 -

of course, for the C-terminus of a C-terminal intracellular domain fragment) or located within the substituted domain.

Preferably all domains for the chimeric receptor other than the substituted domains are complete and contiguous with each other, so that the resulting chimeric receptor has the same sequence (starting at the N-terminus of the chimeric receptor) as the recipient receptor from the N-terminus of the recipient receptor to the C-terminus of the second extracellular domain and from the N-terminus of the third extracellular domain to the N-terminus of the seventh TM domain.

In a first aspect, the invention provides a chimeric NPY receptor protein having the amino acid sequence of an NPY5 receptor protein except that a third intracellular loop domain fragment of the Y5 receptor recipient is replaced by a third intracellular loop domain fragment of another (donor) NPY receptor.

In another aspect this invention provides a chimeric NPY receptor protein having the amino acid sequence of an NPY5 receptor protein except that a the C-terminal intracellular (hydrophilic) domain fragment of this protein is replaced by a corresponding fragment of the corresponding domain of another (donor) NPY receptor.

In a third aspect the invention provides a chimeric NPY receptor having the amino acid sequence of an NPY5 receptor protein except that the chimeric receptor includes both of the NPY receptor protein fragment substitutions described in the two preceding paragraphs.

In additional aspects, the invention provides nucleic acid molecules (preferably isolated nucleic acid molecules) encoding the chimeric NPY receptors of the invention as well as cells (preferably animal cells and preferably cultured cells) comprising expression vectors comprising such nucleic acid molecules and thereby expressing the chimeric NPY receptors of the invention. Preferably these cells bind higher levels per cell of an NPY ligand (e.g., NPY or PYY) than do matched control cells comprising matched control expression vectors and thereby expressing matched native (non-chimeric, non-mutant) NPY5 receptors. The invention further provides a novel monkey NPY5 receptor and chimeras comprising NPY5 domains of this monkey receptor.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS OF THE INVENTION

- 13 -

Nucleic Acid Molecules

This invention provides nucleic acid (NA) molecules (including fragments, e.g., PCR products or restriction fragments) that encode chimeric NPY receptor proteins, preferably chimeric Y5/Y1 receptor proteins. Preferably the NA molecules are clones and are isolated NA molecules. In accordance with the invention, these NA molecules include genomic DNA molecules, cDNA molecules, RNA molecules, and modified analogs of such NA molecules, such as phosphorothioate derivatives and the like.

In a first aspect, the invention provides NA molecules (e.g., a clone) encoding a chimeric NPY receptor protein having the amino acid sequence of an NPY5 receptor protein (preferably a human Y5 receptor protein) except that intracellular loop 3 of this protein has been replaced by intracellular loop 3 of an NPY1 receptor protein (preferably a human Y1 receptor protein). In other words, the encoded chimeric protein is structurally characterized as comprising a single polypeptide chain comprising, in N-terminal to C-terminal order, an NPY5 N-terminal extracellular domain, an NPY5 first TM domain, an NPY5 first intracellular loop domain, an NPY5 second TM domain, an NPY5 first extracellular loop domain, an NPY5 third TM domain, an NPY5 second intracellular loop domain, an NPY5 fourth TM domain, an NPY5 second extracellular loop domain, an NPY5 fifth TM domain, an NPY1 third intracellular loop domain, an NPY5 sixth TM domain, an NPY5 third extracellular loop domain, an NPY5 seventh TM domain, and an NPY5 C-terminal intracellular domain. Preferably the donor Y1 moiety in the location of the third intracellular loop domain of the chimeric receptor is a contiguous Y1 sequence that comprises at least one extension partially or completely into one or both of the immediately adjacent TM domains of the donor Y1 receptor, replacing the corresponding sequence(s) of the recipient Y5 receptor. In certain preferred embodiments, the Y1 moiety in the location of the third intracellular loop domain does not comprise the entire third intracellular loop domain, but only a substantial (at least about 15, preferably at least about 20, and most preferably at least 21 amino acids in length) contiguous portion of the entire donor Y1 third intracellular loop domain. In such an embodiment, the replaced portion of intracellular loop 3 of the recipient Y5 receptor includes the amino acids encoded by nucleotides no. 752-1129 of SEQ ID NO:4. Thus in a preferred embodiment the invention provides isolated NA molecules (e.g., an isolated clone) comprising a cDNA sequence (SEQ ID NO:5) encoding the amino acid sequence

- 14 -

of SEQ ID NO:6, referred to as NPY5ΔY1IC3. In a related embodiment, the NA molecule of SEQ ID NO:4 has been altered by the deletion of a fragment consisting essentially of nucleotides 752–1129 of SEQ ID NO:4 and its replacement (in the same in-frame coding orientation) by a fragment consisting essentially of nucleotides 902–964 of SEQ ID NO:1.

In a separate embodiment the invention provides a chimeric NPY receptor protein comprising the amino acid sequence of the N-terminal domain, intracellular loops, extracellular loops and TM domains of a recipient NPY5 receptor protein (preferably a human Y5 receptor protein) and the C-terminal intracellular domain of a donor NPY1 receptor protein (preferably a human Y1 receptor protein). In other words, the encoded chimeric protein is structurally characterized as comprising a single polypeptide chain comprising, in N-terminal to C-terminal order, an NPY5 N-terminal extracellular domain, an NPY5 first TM domain, an NPY5 first intracellular loop domain, an NPY5 second TM domain, an NPY5 first extracellular loop domain, an NPY5 third TM domain, an NPY5 second intracellular loop domain, an NPY5 fourth TM domain, an NPY5 second extracellular loop domain, an NPY5 fifth TM domain, an NPY5 third intracellular loop domain, an NPY5 sixth TM domain, an NPY5 third extracellular loop domain, at least part of an NPY5 seventh TM domain, and an NPY1 C-terminal intracellular domain.

In certain aspects of the invention, the Y1 C-terminal intracellular domain is a contiguous Y1 sequence that extends partially or completely into the immediately adjacent TM domain of Y1, replacing the corresponding sequence of the Y5 receptor. In certain preferred embodiments, the Y1 moiety in the location of the C-terminal intracellular domain does not comprise the entire C-terminal intracellular domain, but only a substantial (at least about 40, preferably at least about 50, and most preferably at least 57 amino acids in length) contiguous portion of the entire Y1 C-terminal intracellular domain, preferably the Y1 moiety extends to and includes the C-terminal amino acid of Y1 (i.e., the C-terminus of the Y1 C-terminal intracellular domain). In another preferred embodiment the donor C-terminal domain in the chimeric receptor includes all of the amino acids from the C-terminal end of the donor seventh TM domain to the C-terminus of the donor receptor.

More preferably the replaced Y5 recipient C-terminal domain includes the amino acids encoded by nucleotides no. 1343–1384 of SEQ ID NO:4. In a preferred

- 15 -

embodiment the invention provides isolated NA molecules comprising the cDNA sequence of SEQ ID NO:7 (NPY5ΔY1CT). In a related embodiment, the NA molecule of SEQ ID NO:4 has been altered by the deletion of a fragment consisting essentially of nucleotides 1343–1384 of SEQ ID NO:4 and its replacement (in the same in-frame coding orientation) by a fragment consisting essentially of nucleotides 1178–1351 of SEQ ID NO:1.

In another embodiment the invention provides isolated NA molecules encoding the amino acid sequence of a recipient NPY5 receptor protein (preferably a human Y5 receptor protein) except that intracellular loop 3 of this protein has been replaced intracellular loop 3 of an NPY1 receptor protein (preferably a human Y1 receptor protein) and the C-terminal intracellular domain of this protein has been replaced by the C-terminal intracellular domain of an NPY1 receptor protein (preferably the same Y1 receptor protein as that providing the third intracellular loop domain, preferably a human Y1 receptor protein). In other words, the encoded chimeric protein is structurally characterized as comprising a single polypeptide chain comprising, in N-terminal to C-terminal order, an NPY5 N-terminal extracellular domain, an NPY5 first TM domain, an NPY5 first intracellular loop domain, an NPY5 second TM domain, an NPY5 first extracellular loop domain, an NPY5 third TM domain, an NPY5 second intracellular loop domain, an NPY5 fourth TM domain, an NPY5 second extracellular loop domain, at least part of an NPY5 fifth TM domain, an NPY1 third intracellular loop domain, at least part of an NPY5 sixth TM domain, an NPY5 third extracellular loop domain, at least part of an NPY5 seventh TM domain, and an NPY1 C-terminal intracellular domain.

Intracellular loop 3 and the C-terminal domain in this chimeric receptor protein are as described above. In a preferred embodiment the invention provides NA molecules comprising the cDNA sequence of SEQ ID NO:8 (encoding NPY5ΔY1IC3/ΔY1CT). In a related embodiment, the NA molecule of SEQ ID NO:4 has been altered by the deletion of a fragment consisting essentially of nucleotides 752–1129 of SEQ ID NO:4 and its replacement (in the same in-frame coding orientation) by a fragment consisting essentially of nucleotides 902–964 of SEQ ID NO:1 and the NA molecule of SEQ ID NO:4 has been further altered by the deletion of a fragment consisting essentially of nucleotides 1343–1384 of SEQ ID NO:4 and its replacement (in the same in-frame

- 16 -

coding orientation) by a fragment consisting essentially of nucleotides 1178-1351 of SEQ ID NO:1.

This invention also includes NA molecules (preferably isolated, preferably a clone thereof) encoding an amino acid sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27 and SEQ ID NO:31, as well as NA molecules (preferably isolated, preferably a clone thereof) comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:30.

It will be apparent to those skilled in the art that, due to the degeneracy of the genetic code, substituting 1 or more redundant codons can create numerous variants of the described NA molecules without changing the amino acid sequence of the encoded protein product. Additionally, sequence changes may be made in the non-coding regions of NA sequences without altering the amino acid sequence of the encoded protein product.

Also within the scope of the present invention are certain changes to DNA and cDNA sequences encoding the chimeric NPY receptor proteins of SEQ ID NO:6, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, and SEQ ID NO:27. These include in-frame additions of NA sequences encoding short amino acid sequences useful as antibody recognition (tag) sequences. Such amino acid sequences are well known in the art, and include, but are not limited to the His-6x (hexa-histidine or His tag) epitope (SEQ ID NO:11) which chelates metals such as nickel (facilitating protein purification via metal chelation chromatography) and is specifically bound by Monoclonal Anti-polyhistidine Clone HIS-1 antibody (Sigma, St. Louis No.H1029), and the FLAG epitope (SEQ ID NO:12) which is specifically bound by the FLAG-M2 monoclonal antibody (Sigma, St. Louis No. F3165). Techniques for making such modifications are also well known in the art, and may be readily carried out using routine methods or by using prepared kits, for example, the Sigma Mammalian FLAG Expression Kits (Sigma, St. Louis, e.g., Nos. FL-MA and FL-MC). Preferably the fusions are made as in-frame amino- (N-) or carboxy- (C-) terminal fusions. C-terminal fusions are preferred as generally being less prone to interfering with efficient membrane insertion of the fusion protein.

- 17 -

A tagged fusion protein may be purified using an antibody specific for the tag, e.g., by affinity chromatography. Such purification procedures will typically require detergent extraction unless the protein to be purified is not inserted in a membrane. Such purified proteins are useful as antigens for the preparation of receptor-specific antibodies, in which case the retention of receptor signal transduction function is typically of no consequence. Additional embodiments of NA molecules of the invention are those encoding the polypeptides of the invention discussed below (particularly those that have not been previously described herein; see, e.g., A) B) and C)).

Polypeptides

The present invention provides chimeric NPY receptor polypeptides (preferably isolated polypeptides) encoded by the NA molecules described above. In certain preferred embodiments, the chimeric polypeptides of the invention have the amino acid sequence of SEQ ID NO:6, SEQ ID NO:9, or SEQ ID NO:10. The amino acid sequence of SEQ ID NO:6 is the protein product encoded by SEQ ID NO:5, the amino acid sequence of SEQ ID NO:9 is the protein product encoded by SEQ ID NO:7, and the amino acid sequence of SEQ ID NO:10 is the protein product encoded by SEQ ID NO:8. In certain additional preferred embodiments, the chimeric polypeptides of the invention have the amino acid sequence of SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, or SEQ ID NO:27. The invention also encompasses chimeric NPY receptor proteins having amino acid sequences that differ from these, as described above in the discussion of NA molecules.

In additional embodiments, the invention provides:

A) A chimeric receptor protein comprising a single continuous polypeptide chain comprising, in N-terminal to C-terminal order, an NPY5 N-terminal extracellular domain, an NPY5 first TM domain, an NPY5 first intracellular loop domain, an NPY5 second TM domain, an NPY5 first extracellular loop domain, an NPY5 third TM domain, an NPY5 second intracellular loop domain, an NPY5 fourth TM domain, an NPY5 second extracellular loop domain, an NPY5 fifth TM domain optionally substituted at the C-terminal end of the domain with up to 20 amino acids of a contiguous corresponding C-terminal portion of an NPY1 fifth TM domain (when so substituted, such an optionally substituted TM domain being referred to as a "hybrid Y5/Y1 TM domain"), a third intracellular loop domain comprising at least a substantial contiguous portion of an NPY1

- 18 -

third intracellular loop domain, an NPY5 sixth TM domain optionally substituted at the N-terminal end of the domain with up to 20 amino acids of a contiguous corresponding N-terminal portion of an NPY1 sixth TM domain to yield a hybrid Y5/Y1 TM domain, an NPY5 third extracellular loop domain, an NPY5 seventh TM domain, and an NPY5 C-terminal intracellular domain: provided that when either the fifth or sixth TM domain is a hybrid Y5/Y1 TM domain, the portion of an NPY1 third intracellular loop domain is a portion that is contiguous with the corresponding TM domain in native NPY1, and that when both the fifth and sixth TM domains are hybrid Y5/Y1 TM domains, the portion of an NPY1 third intracellular loop domain is an entire NPY1 third intracellular loop domain. Preferably this chimeric receptor protein polypeptide chain consists of about from 335 to 365 amino acids. More preferably this chimeric receptor protein polypeptide chain consists of from 341 to 352 amino acids optionally extended by the addition of a tag sequence of about 6 to 8 amino acids. Most preferably this chimeric receptor protein polypeptide chain consists of 341, 350, or 352 amino acids, each optionally extended by the addition of a tag sequence of about 6 to 8 amino acids.

B) A chimeric receptor protein comprising a single continuous polypeptide chain comprising, in N-terminal to C-terminal order, an NPY5 N-terminal extracellular domain, an NPY5 first TM domain, an NPY5 first intracellular loop domain, an NPY5 second TM domain, an NPY5 first extracellular loop domain, an NPY5 third TM domain, an NPY5 second intracellular loop domain, an NPY5 fourth TM domain, an NPY5 second extracellular loop domain, an NPY5 fifth TM domain, an NPY5 third intracellular loop domain, an NPY5 sixth TM domain, an NPY5 third extracellular loop domain, an NPY5 seventh TM domain optionally substituted at the C-terminal end of the domain with up to 20 amino acids of a contiguous corresponding C-terminal portion of an NPY1 seventh TM domain to yield a hybrid Y5/Y1 TM domain, and at least a substantial portion of an NPY1 C-terminal intracellular domain: provided that when the seventh TM domain is a hybrid Y5/Y1 TM domain, the portion of an NPY1 C-terminal intracellular domain is a portion that (both in the native NPY1 donor receptor and in the resulting chimeric receptor) is contiguous with the seventh TM domain. Preferably this chimeric receptor protein polypeptide chain consists of about from 485 to 516 amino acids. More preferably this chimeric receptor protein polypeptide chain consists of from 488 to 508 amino acids optionally extended by the addition of a tag sequence of about 6 to 8 amino

- 19 -

acids. Most preferably this chimeric receptor protein polypeptide chain consists of 488, 499, or 508 amino acids, each optionally extended by the addition of a tag sequence of about 6 to 8 amino acids.

C) A chimeric receptor protein comprising a single continuous polypeptide chain comprising, in N-terminal to C-terminal order, an NPY5 N-terminal extracellular domain, an NPY5 first TM domain, an NPY5 first intracellular loop domain, an NPY5 second TM domain, an NPY5 first extracellular loop domain, an NPY5 third TM domain, an NPY5 second intracellular loop domain, an NPY5 fourth TM domain, an NPY5 second extracellular loop domain, an NPY5 fifth TM domain optionally substituted at the C-terminal end of the domain with up to 20 amino acids of a contiguous corresponding C-terminal portion of an NPY1 fifth TM domain to yield a hybrid Y5/Y1 TM domain, a third intracellular loop domain comprising at least a substantial contiguous portion of an NPY1 third intracellular loop domain, an NPY5 sixth TM domain optionally substituted at the N-terminal end of the domain with up to 20 amino acids of a contiguous corresponding N-terminal portion of an NPY1 sixth TM domain to yield a hybrid Y5/Y1 TM domain, an NPY5 third extracellular loop domain, an NPY5 seventh TM domain optionally substituted at the C-terminal end of the domain with up to 20 amino acids of a contiguous corresponding C-terminal portion of an NPY1 seventh TM domain to yield a hybrid Y5/Y1 TM domain, and at least a substantial portion of an NPY1 C-terminal intracellular domain: provided that when either the fifth or sixth TM domain is so optionally substituted, the portion of an NPY1 third intracellular loop domain is a portion that is contiguous with the optionally substituted TM domain in native NPY1, that when both the fifth and sixth TM domains are so optionally coupled, the portion of an NPY1 third intracellular loop domain is an entire NPY1 third intracellular loop domain, and that when the seventh TM domain is so optionally substituted, the portion of an NPY1 C-terminal intracellular domain is a portion that (both in the native NPY1 donor receptor and in the resulting chimeric receptor) is contiguous with the seventh TM domain. Preferably this chimeric receptor protein polypeptide chain consists of about from 380 to 405 amino acids. More preferably this chimeric receptor protein polypeptide chain consists of from 383 to 395 amino acids optionally extended by the addition of a tag sequence of about 6 to 8 amino acids. Most preferably this chimeric receptor protein

- 20 -

polypeptide chain consists of 383, 394, or 395 amino acids, each optionally extended by the addition of a tag sequence of about 6 to 8 amino acids.

Expression Systems

Expression systems that may be used in the practice of certain aspects of the invention include but are not limited to insect cell systems infected with recombinant virus expression vectors (for example, baculovirus) comprising the NA molecules of the invention and mammalian cell systems (for example, COS, CHO, BHK, 293, VERO, HeLa, MDCK, WI38, and NIH 3T3 cells) harboring recombinant expression constructs comprising the NA molecules of the invention. Such mammalian vectors should contain promoters, preferably derived from the genome of mammalian cells (for example, the metallothionein promoter) or from mammalian viruses (for example, the adenovirus late promoter, the CMV promoter and the vaccinia virus 7.5K promoter). Such promoters should be operatively linked to a NA fragment of the invention.

Another preferred expression system is an amphibian oocyte comprising RNA molecules of the invention generated, preferably via an in vitro transcription system, using an expression vector of the invention. Preferably the amphibian is a frog, most preferably the African clawed frog, *Xenopus laevis*.

An expression vector of the invention is a vector for recombinant expression of a chimeric receptor protein of the invention, wherein a nucleic acid of the invention is operatively linked to at least one regulatory element (wherein a regulatory element is a nucleic acid sequence that directs the expression of adjacently linked coding sequences) in the appropriate orientation for expression. Such a vector is preferably a plasmid or viral vector.

A cell of the invention is one comprising an expression vector of the invention, and thereby expressing at least one chimeric NPY receptor of the invention.

An insect system utilizing a baculovirus such as *Autographa californica* nuclear polyhedrosis virus (AcNPV) can be used to express the recombinant receptors of the invention. The virus grows in insect cells such as *Spodoptera frugiperda* cells (e.g. Sf9). The coding sequence encoding the chimeric NPY receptor of the invention is typically inserted (e.g., ligated) into non-essential regions of the virus (for example into the polyhedrin gene) and placed under control of an AcNPV promoter (for example the polyhedrin promoter). Preferably the successful introduction of the insert will result in

- 21 -

inactivation of a viral gene. For example, when targeted into the polyhedrin gene, the successful incorporation of the insert will inactivate that gene and result in production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene). The resulting recombinant viruses are then used to infect insect cells, preferably *Spodoptera frugiperda* cells, in which the inserted coding sequence is expressed (see, e.g., Smith et al., *J. Virol.*, 46:584, 1983).

In mammalian host cells, a number of expression systems, including viral-based expression systems, may be utilized. In those aspects of the invention involving an animal comprising cells comprising an insert encoding a chimeric receptor of the invention whereby cells of the animal express a chimeric receptor of the invention, i.e., a transgenic animal of the invention, non-viral expression systems are generally preferred.

In cases where an adenoviral vector is used as an expression vector, the nucleic acid molecule of the invention may be ligated to an adenovirus transcription / translation control complex such as the late promoter and tripartite leader sequence. This recombinant gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (for example, region E1 or E3) will result in a recombinant virus that is viable and capable of expressing a chimeric NPY receptor gene product of the invention in infected hosts (for example, see Logan and Shenk, *Proc. Natl. Acad. Sci. USA*, 81:3655-3659, 1984). Specific initiation signals may also be required for efficient translation of inserted nucleic acid molecules. These signals include the ATG initiation codon and adjacent sequences such as ribosome binding sites, which signals and their uses are well known to those of skill in the art. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see, e.g., Bittner et al., *Methods in Enzymol.*, 153:516-544, 1987). A preferred mammalian expression vector is the PCDNA3.1 vector available from INVITROGEN Corporation, Carlsbad, CA.

A preferred expression vector for insertion of a nucleic acid fragment of the invention for expression thereof in amphibian oocytes is the PBLUESCRIPT SK⁻ vector available from STRATAGENE Cloning Systems, La Jolla, CA. Typically such vectors are used to generate chimeric-receptor-encoding RNAs in in-vitro transcription systems, which RNAs are then injected into the oocytes to induce expression of the chimeric receptor of the invention.

- 22 -

While transient expression systems are within the scope of the invention, long-term expression of recombinant proteins, particularly in cultured mammalian cells, is also within its scope. For such long-term expression (which is preferably adapted for high-level expression) stable expression is preferred. Host cells can be transformed with a vector comprising, in appropriate orientations for expression, appropriate expression control elements (for example, promoter, enhancer sequences, transcription terminators, and polyadenylation signals), and (preferably also in functional linkage to expression elements) a selectable marker. Following the introduction of the vector (often following incubation in a non-selective medium to allow for recovery from the stress of vector introduction), engineered cells may be grown in a selective medium. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci that in turn can be cloned and expanded into cell lines. A number of selection systems can be used. For example, the hypoxanthine-guanine phosphoribosyl-transferase (Szybalska and Szybalski, *Proc. Natl. Acad. Sci. USA*, 48:2026, 1962), adenine phosphoribosyltransferase (Lowy, et al., *Cell*, 22:817, 1980) and herpes simplex virus thymidine kinase (Wigler, et al., *Cell*, 11:223, 1977) genes can be employed in *hgprt*, *aprt* or *tk* cells, respectively. Also, anti-metabolite resistance can be used as the basis of selection for genes such as: *dhfr*, which confers resistance to methotrexate (Wigler et al., *Proc. Natl. Acad. Sci. USA*, 77:3567, 1980; O'Hare et al., *Proc. Natl. Acad. Sci. USA*, 78:1527, 1981); *gpt*, which confers resistance to mycophenolic acid (Mulligan and Berg, *Proc. Natl. Acad. Sci. USA*, 78:2072, 1981); *neo*, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin et al., *J. Mol. Biol.*, 150:1, 1981); *hygro*, which confers resistance to hygromycin (Santerre et al., *Gene*, 30:147, 1984); and *puro*, which confers resistance to puromycin (Ausubel, et al., eds., *Current Protocols in Molecular Biology*, John Wiley & Sons, 1999).

Isolated Membranes of Recombinant Cells

In certain of its aspects the present invention provides a preparation comprising isolated membranes of the recombinant cells of the invention (also referred to herein and in the claims as a preparation of recombinant membranes). Preferably, the isolated membranes should exhibit neuropeptide Y binding activity that is at least 2-fold greater, preferably 10-fold greater and more preferably at least 20-fold greater than that exhibited by control membranes isolated from a control host cell (e.g., a cell of the same cell line

- 23 -

used to prepare the recombinant cell of the invention that does not contain any vector, or contains a control vector that does not encode an NPY receptor). Preferred membranes contain at least 0.1 pmol, more preferably at least 1 pmol, and most preferably at least 5 pmol of chimeric NPY receptor protein per mg of total membrane protein. Membranes
5 can be isolated by any suitable method, such as any of the membrane preparation methods that are routinely used in the art.

Assays

The assays of the present invention involve contacting a compound to be tested with cells or isolated membranes of the invention and detecting the binding of the
10 compounds to the cells or membranes. These assays are useful, e.g., for identifying or characterizing compounds that specifically bind to NPY5 receptors, which compounds are useful, e.g., as tools for receptor mapping and as pharmaceutical agents.

Assays for detecting compounds that interact with NPY receptors are well known in the art, and can be readily adapted to be assays of the invention by using (as substrates
15 for receptor binding) cells or membranes of the invention, rather than those previously known in the art. Such assays typically involve measuring responses of receptors to being contacted with a compound to be tested (functional assays) or measuring the capacity of a compound to be tested to displace the receptor binding of a labeled (e.g., radiolabeled) compound known to bind to such a receptor (binding assays). An
20 exemplary binding assay of the invention is set forth below as Example 5. In such an assay of the invention, a compound to be tested is used as a cold displacer. An exemplary functional assay of the invention is set forth below as Example 6. In such an assay of the invention, a compound to be tested is used as was the agonist in Example 6. Other functional assays of the invention use cells of the invention as substrates and measure
25 cellular responses to being contacted with compounds to be tested.

The aforementioned assays, which identify test compounds which interact with the chimeric receptors and modulate intracellular signalling, can be used to diagnose or treat conditions including, but not limited to, obesity, high/low blood pressure, anxiety, epilepsy, Huntington's, and Parkinson's.

30 Pharmaceutically useful compositions comprising modulators of chimeric receptor activity, identified from the screening assays, may be formulated. Such therapeutic or

- 24 -

diagnostic compositions may be administered to a subject in amounts effective to treat or diagnose disorders.

EXAMPLES

Example 1

5 DNA clones encoding NPY Receptors

Human Y5 receptor was cloned from genomic DNA using a 5' Primer (SEQ ID NO:14) TTTTGGTTGCTGACAAATGTC and a 3' Primer (SEQ ID NO:15)

10 CCTTGGTAAACAGTGAGAATTATTAC. The full length PCR product was initially cloned into the vector pCR 2.1 (Invitrogen, Carlsbad, CA) and then subcloned into pBluescript SK Minus (pBSSKM, Stratagene, La Jolla CA) to yield clone pNN32. A pBSSKM clone encoding a 5' truncated form of the Y5 receptor was made which deleted the 5' end of the coding region to the Nco I site (located at about residues 508-513 of SEQ ID NO:4). This was designated pNN39.

15 A cDNA encoding the human Y1 Receptor (Genbank Accession number M88461, SEQ ID NO:1) was obtained from Claes Wahlestedt (New York Hospital, Cornell Medical Center, Dept. of Neurology and Neuroscience) and bases 197 to 1433 of SEQ ID NO:1 were subcloned in a series of routine steps into pBSSKM, the resulting clone designated pNN22.

20 For an NPY5/Y1 IC loop 3 chimera, pNN39 was digested with Pst I (located at about residues 748-753 of SEQ ID NO:4) and Bgl II (located at about residues 1130-1135 of SEQ ID NO:4) removing bases 753 to 1130 of SEQ ID NO:4.

 The portion of IC loop 3 from bases 903-964
(TACGCCTAAAAAGGAGAAACAACATGATGGACAAGATGAGAGACAATAAGT
ACAGGTCCAGT) of SEQ ID NO:1, corresponding to amino acids 236-256
25 (IRLKRRNNMMDKMRDNKYRSS) of SEQ ID NO:2, was inserted into Y5 using the HY1L3S sense oligo (SEQ ID NO:16) and the HY1L3AS antisense oligo (SEQ ID NO:17). A reaction mixture containing the 2 oligos was heated to 100 degrees C and allowed to cool slowly to anneal the oligos. The double stranded annealing product was then ligated into the Pst I-Bgl II digested pNN39 to yield plasmid pPB1. The pPB1 insert
30 was then reintroduced into the full-length human Y5 gene (pNN32) at the Cel 2 site (located at about residues 619-625 of SEQ ID NO:4) and the resulting plasmid was

- 25 -

designated pNN42. The coding region of the insert of this vector is found in SEQ ID NO:5, hNPY5ΔY1IC3, and encodes the amino acid sequence of SEQ ID NO:6.

To add the Y1 C-terminus to Y5, an Eco RI site was added to each gene. For Y1, bases 1173 to 1178 (ACTTCC) of SEQ ID NO:1 were mutated to create an Eco RI site via PCR from forward primer HY1R1 (SEQ ID NO:18) to a T3 primer (priming from the multiple cloning site - "MCS" - of pBSSKM). The Y1 3' tail was then isolated by digesting with Eco RI and Xba I (which latter enzyme cuts out the Y1 3' tail in the MCS of pBSSKM). For Y5, bases 1338 to 1343 (GGATTA) of SEQ ID NO:4 were mutated using the PCR reverse primer HY5R1 (SEQ ID NO:19). This primer was paired with a forward primer corresponding to bases 527-551 (GCTACTGTCTGGACACTAGGTTTTG) of SEQ ID NO:4, and PCR carried out with pNN32 as template. The resulting PCR band was cut from the unique Pst I site in the PCR product to the introduced Eco RI site.

pNN39 was then opened Pst I to Xba from the MCS of pBSSKM and the mutated Y5 segment Pst I to Eco RI was mixed with the mutated Y1 3' fragment Eco RI to Xba from the MCS to set up a three-way ligation. The resulting mutated gene fragment was then introduced into the full-length Y5 gene at the Bgl II site as a Bgl II-Xba I fragment to yield construct pNN43. The coding region of the insert of this construct is found in SEQ ID NO:7, NPY5ΔY1CT, and encodes the amino acid sequence of SEQ ID NO:9.

The IC loop 3 + CT tail exchange was obtained by combining the above 2 mutant genes in the following manner. Full length hY5 (pNN32) was digested with Cel II (located at about residues 619-625 of SEQ ID NO:4) and Xba in the vector MCS. The loop 3 mutation pNN42 fragment Cel II to Bgl II was combined with the CT mutation pNN43 fragment Bgl II to Xba (the Xba is in the MCS) resulting in pNN44. The coding region of the insert of this vector is found in to SEQ ID NO:8, hNPY5ΔY1IC3/ΔYCT, and encodes the amino acid sequence of SEQ ID NO:10.

Each of the three chimeric NPY5/NPY1 receptors was then digested with Kpn I and Xba I and separately subcloned into the commercial expression vector pcDNA 3.1+ (Invitrogen, Carlsbad, CA) for expression in mammalian cells and into the commercial expression vector pBacPAK9 (CLONTECH, Palo Alto, CA) for expression in SF9 cells.

Example 2

- 26 -

Additional NPY Receptors

Additional examples of chimeric NPY receptors of the invention are set forth in the sequence listings as follows. The canine NPY receptor chimeras cNPY5ΔcY1IC3 (SEQ ID NO:20) and (cNPY5ΔcY1IC3/ΔcY1CT SEQ ID NO:21). The murine NPY receptor chimera mNPY5ΔmY1CT (SEQ ID NO:22). The rat NPY receptor chimeras rNPY5ΔrY1IC3 (SEQ ID NO:23), rNPY5ΔrY1CT (SEQ ID NO:24), and (rNPY5ΔrY1IC3ΔrY1CT SEQ ID NO:25). The porcine NPY receptor chimeras pNPY5ΔpY1IC3 (SEQ ID NO:26) and pNPY5ΔpY1CTΔpY1CT (SEQ ID NO:27).

A novel African Green Monkey (AGM) NPY5 receptor was cloned via PCR from COS cell DNA using the forward primer hY5-45F (SEQ ID NO:28) and the reverse primer hY5-1450R (SEQ ID NO:29), both of which primers were designed using the human NPY5 DNA sequence of SEQ ID NO:4. The forward primer, hY5-45F, comprises 5 bases encoding (with the addition of a sixth base at the 3' end) the first two amino acids of human NPY5. The complete sequence of the AGM NPY5 PCR product is set forth as SEQ ID NO:30 and the amino acid sequence encoded thereby is set forth as SEQ ID NO:31. This amino acid sequence (SEQ ID NO:31) differs from the amino acid sequence of human Y5 (SEQ ID NO:13) in having an arginine instead of a lysine at position 273, an isoleucine instead of a serine at position 275 and a methionine instead of a valine at position 447.

EXAMPLE 3Baculoviral Preparations

Each Baculoviral expression vector was co-transfected along with BACULOGOLD DNA (BD PHARMINGEN, San Diego, CA) into Sf9 insect cells. The Sf9 cell culture supernatant was harvested three days post-transfection. The recombinant virus-containing supernatant was serially diluted in Hink's TNM-FH insect medium (JRH Biosciences, Kansas City) supplemented Grace's salts and with 4.1mM L-Gln, 3.3 g/L LAH, 3.3 g/L ultrafiltered yeastolate and 10% heat-inactivated fetal bovine serum (hereinafter "insect medium") and plaque assayed for recombinant plaques. After four days, recombinant plaques were selected and harvested into 1 ml of insect medium for amplification. Each 1 ml volume of recombinant baculovirus (at passage 0) was used to infect a separate T25 flask containing 2×10^6 Sf9 cells in 5 mls of insect medium. After

- 27 -

five days of incubation at 27°C, supernatant medium was harvested from each of the T25 infections for use as passage 1 inoculum. Two of the seven recombinant baculoviral clones were then chosen for a second round of amplification, using 1 ml of passage 1 stock to infect 1×10^8 cells in 100 ml of insect medium divided into 2 T175 flasks. Forty-eight hours post infection, passage 2 medium from each 100ml prep was harvested and plaque assayed for titer. The cell pellets from the second round of amplification were assayed by affinity binding as described below in Example 5 to verify recombinant receptor expression. A third round of amplification was then initiated using a multiplicity of infection (M.O.I.) of 0.1 to infect a liter of Sf9 cells. Forty hours post-infection the supernatant medium was harvested to yield passage 3 baculoviral stock and the cell pellet assayed for affinity binding. Titer of the passage 3 baculoviral stock was determined by plaque assay and an M.O.I. and Incubation Time Course experiment was carried out to determine conditions for optimal receptor expression. Results from the receptor optimization experiment show that an M.O.I. of 0.1 and a 72 hour incubation were the ideal infection parameters in order to achieve optimum Y5 receptor expression in up to 1 liter Sf9 cell infection cultures.

Log-phase Sf9 cells were infected with a stock of recombinant baculovirus (prepared as described for Y5, above) encoding either NPY5 (SEQ ID NO:13), NPY5 Y1IC3 (SEQ ID NO:6), or NPY5ΔY1CT (SEQ ID NO:9) followed by culturing in insect medium at 27°C. 72 hours post-infection, a sample of cell suspension was analyzed for viability by trypan blue dye exclusion, and the remaining Sf9 cells were harvested via centrifugation (3000 rpm/ 10 minutes/ 4°C).

EXAMPLE 4

Purified Membranes

Sf9 cell pellets prepared in Example 3 were resuspended in homogenization buffer (10 mM HEPES, 250 mM sucrose, 0.5 µg/ml leupeptin, 2 µg/ml Aprotinin, 200 µM PMSF, and 2.5 mM EDTA, pH 7.4) and homogenized using a POLYTRON homogenizer (setting 5 for 30 seconds). The homogenate was centrifuged (536 x g/ 10 minutes/ 4°C) to pellet the nuclei. The supernatant containing isolated membranes was decanted to a clean centrifuge tube, centrifuged (48,000 X g/ 30 minutes, 4°C) and resuspended in 30 ml homogenization buffer. This centrifugation and resuspension step was repeated twice. The final pellet was resuspended in ice cold Dulbecco's PBS containing 5 mM EDTA and

- 28 -

stored at -80°C in aliquots until needed. The protein concentration of the resulting membrane preparation was measured using the Bradford protein assay (Bio-Rad Laboratories, Hercules, CA). By this measure, a 1-liter culture of cells typically yielded 100-125 mg of total membrane protein.

5

EXAMPLE 5

Radioligand Binding Assays for Modulators of Chimeric Receptors

Purified P2 membranes, prepared by the method given above in Example 4, were washed with PBS and resuspended by Dounce homogenization (tight pestle) in binding buffer (50 mM Tris-HCl, 5 mM KCl, 120 mM NaCl, 2 mM CaCl_2 , 1 mM MgCl_2 , 0.1% BSA, pH 7.4).

For saturation binding analysis, membranes (5-50 μg) were added to polypropylene tubes containing 0.010-0.500nM [^{125}I]PYY (porcine, New England Nuclear Corp., Boston, MA; Sigma Biochemicals and Reagents 2000-2001; No. P5801). For evaluation of guanine nucleotide effects on receptor affinity, GTP γ S was added to duplicate tubes at a final concentration of 50 μM . Table I shows an [^{125}I]PYY saturation summary with PYY binding kinetics and receptor expression levels for each receptor construct as indicated.

The data in Table I indicate that both chimeric constructs demonstrate equivalent or lower K_d , suggesting equivalent or higher receptor affinities for PYY, as compared with the native NPY5 receptor. The data also show that there is increased expression of both chimeric receptors on cell membranes.

For competition analysis (Table II), membranes (5-50 μg) were added to polypropylene tubes containing 0.050nM [^{125}I]PYY (porcine). Cold displacers ("Peptide") specifically human NPY 1-36, human NPY 3-36, human NPY 13-36, human D-Trp 32 NPY and human pancreatic polypeptide - "hPP", all from American Peptide Co., Sunnyvale, CA, were added to separate assays at concentrations ranging from 10^{-12} M to 10^{-6} M to yield a final volume of 0.250 mL. These peptides allow for the discrimination of specific NPY receptor pharmacological profiles. Nonspecific binding was determined in the presence of 1 μM NPY (human, American Peptide Co., Sunnyvale, CA) and accounted for less than 10% of total binding. Following a 2-hour incubation at room temperature, the reaction was terminated by rapid vacuum filtration. Samples were filtered over presoaked (in 1.0% polyethyleneimine for 2 hours prior to use) GF/C

- 29 -

WHATMAN filters and rinsed 2 times with 5 mLs cold binding buffer without BSA. Remaining bound radioactivity was quantified by gamma counting. K_i and Hill coefficient ("nH") were determined by fitting the Hill equation to the measured values with the aid of SIGMAPLOT software (SPSS Inc., Chicago).

- 5 It is theorized, from the data in Table II, that changes in the amino acid sequences of receptor domains from those of native NPY5 may change the structural conformation of the receptor upon ligand binding thus affecting the receptor affinity for [125 I] PYY.

TABLE I

| NPY5 Receptor | | Kd (nM)* | Bmax (fmol/gm)* |
|---------------------|----------------------------|-----------------|-----------------|
| NPY5 | | 0.183 \pm .04 | 484 \pm 295 |
| | +50 μ M GTP γ S | 0.398 \pm .11 | 503 \pm 295 |
| NPY5 Δ Y1IC3 | | 0.082 \pm .02 | 1573 \pm 816 |
| | +50 μ M GTP γ S | 0.110 \pm .01 | 1555 \pm 842 |
| NPY5 Δ Y1CT | | 0.207 \pm .05 | 949 \pm 175 |
| | +50 μ M GTP γ S | 0.332 \pm .05 | 950 \pm 71 |

*Average \pm standard deviation

10

TABLE II

| DISPLACER | NPY5 | | NPY5 Δ Y1IC3 | | NPY5 Δ Y1CT | |
|--------------|---------|-----|---------------------|-----|--------------------|-----|
| | Ki (nM) | nH | Ki (nM) | nH | Ki (nM) | nH |
| HNPY 1-36 | 0.44 | 0.7 | 0.57 | 1.0 | 0.40 | 0.7 |
| HNPY 2-36 | 0.37 | 0.9 | 0.29 | 0.9 | 0.80 | 0.7 |
| HNPY 3-36 | 2.10 | 0.7 | 1.20 | 1.2 | 1.90 | 0.6 |
| HNPY 13-36 | 20.00 | 0.7 | 10.30 | 1.0 | 23.40 | 0.5 |
| HPP | 0.53 | 0.6 | 0.15 | 0.8 | 0.31 | 0.7 |
| D-Trp 32 NPY | 8.00 | 0.7 | 2.30 | 0.8 | 15.60 | 0.9 |

EXAMPLE 6**Functional Assays of Chimeric NPY Receptors**

15

GTP γ 35 S binding activity was measured using a modification of the method of Wieland and Jacobs, *Methods Enzymol* 237:3-13, 1994. Results are set forth in Fig. 1.

- 30 -

For each receptor construct tested, four baculoviral expression vector stocks were used to infect a culture of *Sf9* cells (as described above in Example 3) with an MOI of 1:1:1:1. These four consisted of one vector encoding the NPY receptor construct being tested (prepared as described above) and a different commercially obtained baculoviral expression vector stock encoding each of the three subunits of a heterotrimeric G-protein.

In particular, the NPY expression vector constructs, as indicated in Fig. 1, were those comprising, in appropriate orientation for expression, the Y1 receptor cDNA of SEQ ID NO:1 (filled bars), the NPY5 receptor cDNA of SEQ ID NO:4 (open bars), the chimeric NPY5ΔY1CT receptor cDNA of SEQ ID NO:7 (vertical stripes), or the chimeric NPY5ΔY1IC3 receptor cDNA of SEQ ID NO:5 (horizontal stripes). The G-protein-encoding virus stocks were obtained from BIOSIGNAL Inc., Montreal, and were 1) a $G\alpha$ G-protein subunit-encoding virus stock as indicated in Fig. 1 below the X axis (wherein $i2$ indicates the rat $G\alpha_{i2}$ G-protein-encoding virus stock BIOSIGNAL #V5J008 and O indicates the rat $G\alpha_o$ G-protein-encoding virus stock BIOSIGNAL #V5H010), 2) a bovine $\beta 1$ G-protein-encoding virus stock (BIOSIGNAL #V5H012), and 3) a human $\gamma 2$ G-protein-encoding virus stock (BIOSIGNAL #V6B003). Agonist-stimulated $GTP\gamma^{35}S$ binding on purified membranes was assessed using hNPY 1-36 (American Peptide Co., Sunnyvale, CA) as agonist in order to ascertain which receptor/ $G\alpha\beta\gamma$ combination(s) yielded the maximal functional activity as measured by $GTP\gamma^{35}S$ binding.

Purified membranes, prepared by the method given above in Example 4, were resuspended by Dounce homogenization (tight pestle) in $GTP\gamma^{35}S$ binding assay buffer (50 mM Tris pH 7.0, 120 mM NaCl, 2 mM $MgCl_2$, 2 mM EGTA, 0.1% BSA, 0.1 mM bacitracin, 100KIU/mL Aprotinin, 5 μM GDP) and added to reaction tubes at a concentration of 30 μg /reaction tube. After adding increasing doses of the agonist hNPY 1-36 (American Peptide Co., Sunnyvale, CA), reactions were initiated by the addition of 100 pM $GTP\gamma^{35}S$. Following a 30-minute incubation at room temperature, the reactions were terminated by vacuum filtration over GF/C filters (pre-soaked in wash buffer, 0.1% BSA) followed by washing with ice-cold wash buffer (50 mM Tris pH 7.0, 120mM NaCl).

Bound $GTP\gamma^{35}S$ was determined by liquid scintillation spectrometry of the washed filters. Non-specific binding was determined using 10 mM $GTP\gamma S$ and represented less

- 31 -

than 5 percent of total binding. Data is expressed as % maximal response and was derived by determining the maximal agonist stimulated % above basal stimulation for each receptor type, and normalizing all other data within that receptor type to the maximal (100%) value. The results of these GTP γ ³⁵S binding experiments were analyzed
5 using SIGMAPLOT software (SPSS Inc., Chicago).

Results are shown in Figure 1 and discussed in the Brief Description of the Drawings.

The data suggest that G protein subtypes are functionally distinct, affecting receptor/G $\alpha\beta\gamma$ binding interactions and consequently the maximal functional activity of
10 the native and chimeric receptors as measured by the GTP for GDP exchange on the G alpha subunit of the G-protein complex.

- 32 -

CLAIMS

1. A chimeric receptor protein comprising a single polypeptide chain of amino acids, said protein comprising, in N-terminal to C-terminal order and immediately adjacent to each other and without further intervening amino acids, the following amino acid
5 sequence domains:
- a) an NPY5 receptor N-terminal extracellular domain,
 - b) an NPY5 receptor first transmembrane domain,
 - c) an NPY5 receptor first intracellular loop domain,
 - d) an NPY5 receptor second transmembrane domain,
 - 10 e) an NPY5 receptor first extracellular loop domain,
 - f) an NPY5 receptor third transmembrane domain,
 - g) an NPY5 receptor second intracellular loop domain,
 - h) an NPY5 receptor fourth transmembrane domain,
 - i) an NPY5 receptor second extracellular loop domain,
 - 15 j) an NPY receptor fifth transmembrane domain,
 - k) an NPY1 receptor third intracellular loop domain,
 - l) an NPY receptor sixth transmembrane domain,
 - m) an NPY5 receptor third extracellular loop domain,
 - n) an NPY5 receptor seventh transmembrane domain, and
 - 20 o) an NPY5 receptor C-terminal intracellular domain.
2. A chimeric receptor protein according to claim 1, in which the NPY receptor of the fifth transmembrane domain and the sixth transmembrane domain are selected from NPY1 and NPY5 receptors.
3. A chimeric receptor protein according to claim 1, in which each domain is
25 independently selected from human, monkey, dog, mouse, pig, guinea pig, and rat receptors.
4. A chimeric receptor protein comprising a single polypeptide chain of amino acids, said protein comprising, in N-terminal to C-terminal order and immediately adjacent to each other and without further intervening amino acids, the following amino acid
30 sequence domains:
- a) an NPY5 receptor N-terminal extracellular domain,
 - b) an NPY5 receptor first transmembrane domain,

- 33 -

- c) an NPY5 receptor first intracellular loop domain,
 - d) an NPY5 receptor second transmembrane domain,
 - e) an NPY5 receptor first extracellular loop domain,
 - f) an NPY5 receptor third transmembrane domain,
 - 5 g) an NPY5 receptor second intracellular loop domain,
 - h) an NPY5 receptor fourth transmembrane domain,
 - i) an NPY5 receptor second extracellular loop domain,
 - j) an NPY5 receptor fifth transmembrane domain,
 - k) an NPY5 receptor third intracellular loop domain,
 - 10 l) an NPY5 receptor sixth transmembrane domain,
 - m) an NPY5 receptor third extracellular loop domain,
 - n) an NPY receptor seventh transmembrane domain, and
 - o) an NPY1 receptor C-terminal intracellular domain.
5. A chimeric receptor protein according to claim 4, in which the NPY receptor of
15 the fifth transmembrane domain and the sixth transmembrane domain are selected from NPY1 and NPY5 receptors.
6. A chimeric receptor protein according to claim 4, in which each domain is independently selected from human, monkey, dog, mouse, pig, guinea pig, and rat receptors.
- 20 7. A chimeric receptor protein comprising a single polypeptide chain of amino acids, said protein comprising, in N-terminal to C-terminal order and immediately adjacent to each other and without further intervening amino acids, the following amino acid sequence domains:
- a) an NPY5 receptor N-terminal extracellular domain,
 - 25 b) an NPY5 receptor first transmembrane domain,
 - c) an NPY5 receptor first intracellular loop domain,
 - d) an NPY5 receptor second transmembrane domain,
 - e) an NPY5 receptor first extracellular loop domain,
 - f) an NPY5 receptor third transmembrane domain,
 - 30 g) an NPY5 receptor second intracellular loop domain,
 - h) an NPY5 receptor fourth transmembrane domain,
 - i) an NPY5 receptor second extracellular loop domain,

- 34 -

- j) an NPY receptor fifth transmembrane domain,
 - k) an NPY1 receptor third intracellular loop domain,
 - l) an NPY receptor sixth transmembrane domain,
 - m) an NPY5 receptor third extracellular loop domain,
 - 5 n) an NPY receptor seventh transmembrane domain, and
 - o) an NPY1 receptor C-terminal intracellular domain.
8. A chimeric receptor protein according to claim 7, in which the NPY receptor of the fifth transmembrane domain and the sixth transmembrane domain are selected from NPY1 and NPY5 receptors.
- 10 9. A chimeric receptor protein according to claim 7, in which each domain is independently selected from human, monkey, dog, mouse, pig, guinea pig, and rat receptors.
10. An isolated polynucleotide encoding a polypeptide comprising the chimeric receptor protein of claim 1, the receptor protein consisting of the amino acid sequence of
- 15 SEQ. ID NO. 6, or a fragment of said sequence capable of binding a signal transducing ligand for said receptor protein.
11. An isolated polynucleotide encoding a polypeptide comprising the chimeric receptor protein of claim 4, the receptor protein consisting of the amino acid sequence of
- SEQ. ID NO. 9, or a fragment of said sequence capable of binding a signal transducing
- 20 ligand for said receptor protein.
12. An isolated polynucleotide encoding a polypeptide comprising the chimeric receptor protein of claim 7, the receptor protein consisting of the amino acid sequence of
- SEQ. ID NO. 10, or a fragment of said sequence capable of binding a signal transducing
- ligand for said receptor protein.
- 25 13. A nucleic acid molecule encoding the protein of claim 1.
14. A nucleic acid molecule encoding the protein of claim 4.
15. A nucleic acid molecule encoding the protein of claim 7.
16. An isolated polynucleotide encoding a chimeric receptor protein according to claim 1, the polynucleotide consisting of SEQ. ID. NO. 5 and homologues thereof or a
- 30 polynucleotide which hybridizes to the complement of SEQ. ID. NO. 5.

- 35 -

17. An isolated polynucleotide encoding a chimeric receptor protein according to claim 4, the polynucleotide consisting of SEQ. ID. NO. 7 and homologues thereof or a polynucleotide which hybridizes to the complement of SEQ. ID. NO. 7.
18. An isolated polynucleotide encoding a chimeric receptor protein according to claim 7, the polynucleotide consisting of SEQ. ID. NO. 8 and homologues thereof or a polynucleotide which hybridizes to the complement of SEQ. ID. NO. 8.
19. A vector for recombinant expression of a chimeric receptor protein, said vector comprising the nucleic acid molecule of claim 13, operatively linked to at least one regulatory element in the appropriate orientation for expression.
20. A vector for recombinant expression of a chimeric receptor protein, said vector comprising the nucleic acid molecule of claim 14, operatively linked to at least one regulatory element in the appropriate orientation for expression.
21. A vector for recombinant expression of a chimeric receptor protein, said vector comprising the nucleic acid molecule of claim 15, operatively linked to at least one regulatory element in the appropriate orientation for expression.
22. A vector for recombinant expression of a chimeric receptor protein, said vector comprising the polynucleotide of claim 16, operatively linked to at least one regulatory element in the appropriate orientation for expression.
23. A vector for recombinant expression of a chimeric receptor protein, said vector comprising the polynucleotide of claim 17, operatively linked to at least one regulatory element in the appropriate orientation for expression.
24. A vector for recombinant expression of a chimeric receptor protein, said vector comprising the polynucleotide of claim 18, operatively linked to at least one regulatory element in the appropriate orientation for expression.
25. The vector of claim 19, wherein the vector is a plasmid vector.
26. The vector of claim 20, wherein the vector is a plasmid vector.
27. The vector of claim 21, wherein the vector is a plasmid vector.
28. The vector of claim 22, wherein the vector is a plasmid vector.
29. The vector of claim 23, wherein the vector is a plasmid vector.
30. The vector of claim 24, wherein the vector is a plasmid vector.
31. The vector of claim 19, wherein the vector is a viral vector.
32. The vector of claim 20, wherein the vector is a viral vector.

- 36 -

33. The vector of claim 21, wherein the vector is a viral vector.
34. The vector of claim 22, wherein the vector is a viral vector.
35. The vector of claim 23, wherein the vector is a viral vector.
36. The vector of claim 24, wherein the vector is a viral vector.
- 5 37. A recombinant cell comprising the vector of claim 19, said recombinant cell being prepared by introducing said vector into a host cell not containing said vector to generate a vector-containing cell containing said vector, wherein the recombinant cell is the vector-containing cell or its progeny.
38. A recombinant cell comprising the vector of claim 20, said recombinant cell being
10 prepared by introducing said vector into a host cell not containing said vector to generate a vector-containing cell containing said vector, wherein the recombinant cell is the vector-containing cell or its progeny.
39. A recombinant cell comprising the vector of claim 21, said recombinant cell being prepared by introducing said vector into a host cell not containing said vector to generate
15 a vector-containing cell containing said vector, wherein the recombinant cell is the vector-containing cell or its progeny.
40. A recombinant cell comprising the vector of claim 22, said recombinant cell being prepared by introducing said vector into a host cell not containing said vector to generate a vector-containing cell containing said vector, wherein the recombinant cell is the
20 vector-containing cell or its progeny.
41. A recombinant cell comprising the vector of claim 23, said recombinant cell being prepared by introducing said vector into a host cell not containing said vector to generate a vector-containing cell containing said vector, wherein the recombinant cell is the vector-containing cell or its progeny.
- 25 42. A recombinant cell comprising the vector of claim 24, said recombinant cell being prepared by introducing said vector into a host cell not containing said vector to generate a vector-containing cell containing said vector, wherein the recombinant cell is the vector-containing cell or its progeny.
43. The recombinant cell of claim 37, wherein the recombinant cell exhibits
30 neuropeptide Y binding activity that is at least 2-fold greater than that exhibited by the host cell.

- 37 -

44. The recombinant cell of claim 38, wherein the recombinant cell exhibits neuropeptide Y binding activity that is at least 2-fold greater than that exhibited by the host cell.
45. The recombinant cell of claim 39, wherein the recombinant cell exhibits
5 neuropeptide Y binding activity that is at least 2-fold greater than that exhibited by the host cell.
46. The recombinant cell of claim 40, wherein the recombinant cell exhibits neuropeptide Y binding activity that is at least 2-fold greater than that exhibited by the host cell.
- 10 47. The recombinant cell of claim 41, wherein the recombinant cell exhibits neuropeptide Y binding activity that is at least 2-fold greater than that exhibited by the host cell.
48. The recombinant cell of claim 42, wherein the recombinant cell exhibits neuropeptide Y binding activity that is at least 2-fold greater than that exhibited by the
15 host cell.
49. The recombinant cell of claim 43, wherein the host cell is an insect cell.
50. The recombinant cell of claim 44, wherein the host cell is an insect cell.
51. The recombinant cell of claim 45, wherein the host cell is an insect cell.
52. The recombinant cell of claim 46, wherein the host cell is an insect cell.
- 20 53. The recombinant cell of claim 47, wherein the host cell is an insect cell.
54. The recombinant cell of claim 48, wherein the host cell is an insect cell.
55. The recombinant cell of claim 43, wherein the host cell is a mammalian cell.
56. The recombinant cell of claim 44, wherein the host cell is a mammalian cell.
57. The recombinant cell of claim 45, wherein the host cell is a mammalian cell.
- 25 58. The recombinant cell of claim 46, wherein the host cell is a mammalian cell.
59. The recombinant cell of claim 47, wherein the host cell is a mammalian cell.
60. The recombinant cell of claim 48, wherein the host cell is a mammalian cell.
61. An amphibian oocyte comprising an RNA which is the nucleic acid molecule of claim 13.
- 30 62. An amphibian oocyte comprising an RNA which is the nucleic acid molecule of claim 14.

- 38 -

63. An amphibian oocyte comprising an RNA which is the nucleic acid molecule of claim 15.
64. An amphibian oocyte comprising an RNA which is the polynucleotide of claim 16.
- 5 65. An amphibian oocyte comprising an RNA which is the polynucleotide of claim 17.
66. An amphibian oocyte comprising an RNA which is the polynucleotide of claim 18.
67. A preparation of recombinant membranes isolated from a plurality of the
10 recombinant cell of claim 43, wherein the recombinant membranes of the preparation exhibit neuropeptide Y binding activity that is at least 2-fold greater than that exhibited by a control consisting of a matched preparation of membranes isolated from host cells.
68. A preparation of recombinant membranes isolated from a plurality of the
15 recombinant cell of claim 44, wherein the recombinant membranes of the preparation exhibit neuropeptide Y binding activity that is at least 2-fold greater than that exhibited by a control consisting of a matched preparation of membranes isolated from host cells.
69. A preparation of recombinant membranes isolated from a plurality of the
20 recombinant cell of claim 45, wherein the recombinant membranes of the preparation exhibit neuropeptide Y binding activity that is at least 2-fold greater than that exhibited by a control consisting of a matched preparation of membranes isolated from host cells.
70. A preparation of recombinant membranes isolated from a plurality of the
recombinant cell of claim 46, wherein the recombinant membranes of the preparation exhibit neuropeptide Y binding activity that is at least 2-fold greater than that exhibited by a control consisting of a matched preparation of membranes isolated from host cells.
- 25 71. A preparation of recombinant membranes isolated from a plurality of the recombinant cell of claim 47, wherein the recombinant membranes of the preparation exhibit neuropeptide Y binding activity that is at least 2-fold greater than that exhibited by a control consisting of a matched preparation of membranes isolated from host cells.
72. A preparation of recombinant membranes isolated from a plurality of the
30 recombinant cell of claim 48, wherein the recombinant membranes of the preparation exhibit neuropeptide Y binding activity that is at least 2-fold greater than that exhibited by a control consisting of a matched preparation of membranes isolated from host cells.

- 39 -

73. An assay for characterizing a test compound, said assay comprising contacting a chimeric receptor of claim 1, with the test compound and detecting a consequence of the binding of said test compound to said receptor.

74. An assay for characterizing a test compound, said assay comprising contacting a
5 chimeric receptor of claim 4, with the test compound and detecting a consequence of the binding of said test compound to said receptor.

75. An assay for characterizing a test compound, said assay comprising contacting a chimeric receptor of claim 7, with the test compound and detecting a consequence of the binding of said test compound to said receptor.

10 76. The assay of claim 73, wherein the test compound is unlabeled and the consequence is the displacement from the receptor of a labeled compound that binds specifically to the receptor.

77. The assay of claim 74, wherein the test compound is unlabeled and the consequence is the displacement from the receptor of a labeled compound that binds
15 specifically to the receptor.

78. The assay of claim 75, wherein the test compound is unlabeled and the consequence is the displacement from the receptor of a labeled compound that binds specifically to the receptor.

79. The assay of claim 73, wherein the receptor is a membrane-inserted receptor and
20 the consequence is a response associated with at least one intracellular domain of the receptor.

80. The assay of claim 74, wherein the receptor is a membrane-inserted receptor and the consequence is a response associated with at least one intracellular domain of the receptor.

25 81. The assay of claim 75, wherein the receptor is a membrane-inserted receptor and the consequence is a response associated with at least one intracellular domain of the receptor.

82. A method of treating a condition in a subject selected from eating disorders, seizure disorders, blood pressure disorders, locomotor disorders and anxiety disorders,
30 which comprises administering to the subject a therapeutically effective amount of a composition comprising a compound identified as modulating the activity of an NPY receptor by carrying out the assay of claim 73.

- 40 -

83. A method of treating a condition in a subject selected from eating disorders, seizure disorders, blood pressure disorders, locomoter disorders and anxiety disorders, which comprises administering to the subject a therapeutically effective amount of a composition comprising a compound identified as modulating the activity of an NPY
5 receptor by carrying out the assay of claim 74.

84. A method of treating a condition in a subject selected from eating disorders, seizure disorders, blood pressure disorders, locomoter disorders and anxiety disorders, which comprises administering to the subject a therapeutically effective amount of a composition comprising a compound identified as modulating the activity of an NPY
10 receptor by carrying out the assay of claim 75.

85. A method of treating a condition in a subject selected from eating disorders, seizure disorders, blood pressure disorders, locomoter disorders and anxiety disorders, which comprises administering to the subject a therapeutically effective amount of a composition comprising a compound identified as modulating the activity of an NPY
15 receptor by carrying out the assay of claim 76.

86. A method of treating a condition in a subject selected from eating disorders, seizure disorders, blood pressure disorders, locomoter disorders and anxiety disorders, which comprises administering to the subject a therapeutically effective amount of a composition comprising a compound identified as modulating the activity of an NPY
20 receptor by carrying out the assay of claim 77.

87. A method of treating a condition in a subject selected from eating disorders, seizure disorders, blood pressure disorders, locomoter disorders and anxiety disorders, which comprises administering to the subject a therapeutically effective amount of a composition comprising a compound identified as modulating the activity of an NPY
25 receptor by carrying out the assay of claim 78.

88. A method of treating a condition in a subject selected from eating disorders, seizure disorders, blood pressure disorders, locomoter disorders and anxiety disorders, which comprises administering to the subject a therapeutically effective amount of a composition comprising a compound identified as modulating the activity of an NPY
30 receptor by carrying out the assay of claim 79.

89. A method of treating a condition in a subject selected from eating disorders,

- 41 -

seizure disorders, blood pressure disorders, locomoter disorders and anxiety disorders, which comprises administering to the subject a therapeutically effective amount of a composition comprising a compound identified as modulating the activity of an NPY receptor by carrying out the assay of claim 80.


5 90. A method of treating a condition in a subject selected from eating disorders, seizure disorders, blood pressure disorders, locomoter disorders and anxiety disorders, which comprises administering to the subject a therapeutically effective amount of a composition comprising a compound identified as modulating the activity of an NPY receptor by carrying out the assay of claim 81.

10 91. Use of a compound identified as modulating the activity of an NPY receptor by carrying out the assay of any of claims 73 to 81 in the preparation of a medicament for treatment of a condition selected from eating disorders, seizure disorders, locomoter disorders, and anxiety disorders.

15 92. A medicine for treatment of a condition selected from eating disorders, seizure disorders, locomoter disorders, and anxiety disorders which comprises as an active ingredient a compound identified as modulating the activity of an NPY receptor by carrying out the assay of any of claims 73 to 81.

20 93. Use of a compound identified as modulating the activity of an NPY receptor by carrying out the assay of any of claims 73 to 81 for treatment of a condition selected from eating disorders, seizure disorders, locomoter disorders, and anxiety disorders.

FIG. 1



SEQUENCE LISTING

<110> Bennett, Michele
Brodbeck, Robbin
Krause, James

<120> Chimeric Neuropeptide Y Receptors

<130> N2000.001

<140> Not Yet Assigned

<141> 2000-01-28

<160> 31

<170> PatentIn Ver. 2.1

<210> 1

<211> 1605

<212> DNA

<213> Homo sapiens

<400> 1

```
ccttctttaa tgaagcagga gcgaaaaaga caaattccaa agaggattgt tcagttcaag 60
ggaatgaaga attcagaata attttggttaa atggattcca atatggggaa taagaataag 120
ctgaacagtt gacctgcttt gaagaaacat actgtccatt tgtctaaaat aatctataac 180
aaccaaaacca atcaaaatga attcaacatt attttcccag gttgaaaatc attcagtcga 240
ctctaatttc tcagagaaga atgcccagct tctggctttt gaaaatgatg attgtcatct 300
gcccttggcc atgatattta ccttagctct tgcttatgga gctgtgatca ttcttggtgt 360
ctctggaaac ctggccttga tcataatcat cttgaaacaa aaggagatga gaaatgttac 420
caacatcctg attgtgaacc ttctcttctc agacttgctt gttgccatca tgtgtctccc 480
ctttacattt gtctacacat taatggacca ctgggtcttt ggtgaggcga tgtgtaagtt 540
gaatcctttt gtgcaatgtg tttcaatcac tgtgtccatt ttctctctgg ttctcattgc 600
tgttgaacga catcagctga taatcaacc ctcagggtgg agaccaaata atagacatgc 660
ttatgtaggt attgctgtga tttgggtcct tgctgtggct tcttctttgc ctttctctgat 720
ctaccaagta atgactgatg agccgttcca aaatgtaaca cttgatgcgt acaaagacaa 780
atacgtgtgc tttgatcaat ttccatcgga ctctcatagg ttgtcttata ccactctcct 840
cttggtgctg cagtattttg gtccactttg ttttatattt atttgctact tcaagatata 900
tatacgctta aaaaggagaa acaacatgat ggacaagatg agagacaata agtacaggtc 960
cagtgaacc aaaagaatca atatcatgct gctctccatt gtggtagcat ttgcagtctg 1020
ctggctccct cttaccatct ttaacactgt gtttgattgg aatcatcaga tcattgctac 1080
ctgcaaccac aatctgttat tcctgctctg ccacctcaca gcaatgatat ccacttggtg 1140
caaccccata ttttatgggt tcctgaacaa aaacttccag agagacttgc agttcttctt 1200
caacttttgt gatttccggt ctccggatga tgattatgaa acaatagcca tgtccacgat 1260
gcacacagat gtttccaaaa cttctttgaa gcaagcaagc ccagtcgcat ttaaaaaaat 1320
caacaacaat gatgataatg aaaaaatctg aaactactta tagcctatgg tcccggatga 1380
catctgttta aaaacaagca caacctgcaa catactttga ttacctgttc tcccaaggaa 1440
tggtgttgaa atcatttgaa aatgactaag attttcttgt cttgcttttt actgcttttt 1500
ttgtagttgt cataattaca tttggaacaa aagggtgtggg ctttgggggtc ttctggaaat 1560
agttttgacc agacatcttt gaagtgcctt ttgtgaattt accag 1605
```

<210> 2

<211> 384

<212> PRT

<213> Homo sapiens

<400> 2

```

Met Asn Ser Thr Leu Phe Ser Gln Val Glu Asn His Ser Val His Ser
 1           5           10           15

Asn Phe Ser Glu Lys Asn Ala Gln Leu Leu Ala Phe Glu Asn Asp Asp
 20           25           30

Cys His Leu Pro Leu Ala Met Ile Phe Thr Leu Ala Leu Ala Tyr Gly
 35           40           45

Ala Val Ile Ile Leu Gly Val Ser Gly Asn Leu Ala Leu Ile Ile Ile
 50           55           60

Ile Leu Lys Gln Lys Glu Met Arg Asn Val Thr Asn Ile Leu Ile Val
 65           70           75           80

Asn Leu Ser Phe Ser Asp Leu Leu Val Ala Ile Met Cys Leu Pro Phe
      85           90           95

Thr Phe Val Tyr Thr Leu Met Asp His Trp Val Phe Gly Glu Ala Met
100           105           110

Cys Lys Leu Asn Pro Phe Val Gln Cys Val Ser Ile Thr Val Ser Ile
115           120           125

Phe Ser Leu Val Leu Ile Ala Val Glu Arg His Gln Leu Ile Ile Asn
130           135           140

Pro Arg Gly Trp Arg Pro Asn Asn Arg His Ala Tyr Val Gly Ile Ala
145           150           155           160

Val Ile Trp Val Leu Ala Val Ala Ser Ser Leu Pro Phe Leu Ile Tyr
165           170           175

Gln Val Met Thr Asp Glu Pro Phe Gln Asn Val Thr Leu Asp Ala Tyr
180           185           190

Lys Asp Lys Tyr Val Cys Phe Asp Gln Phe Pro Ser Asp Ser His Arg
195           200           205

Leu Ser Tyr Thr Thr Leu Leu Leu Val Leu Gln Tyr Phe Gly Pro Leu
210           215           220

Cys Phe Ile Phe Ile Cys Tyr Phe Lys Ile Tyr Ile Arg Leu Lys Arg
225           230           235           240

Arg Asn Asn Met Met Asp Lys Met Arg Asp Asn Lys Tyr Arg Ser Ser
245           250           255

Glu Thr Lys Arg Ile Asn Ile Met Leu Leu Ser Ile Val Val Ala Phe
260           265           270

Ala Val Cys Trp Leu Pro Leu Thr Ile Phe Asn Thr Val Phe Asp Trp
275           280           285

Asn His Gln Ile Ile Ala Thr Cys Asn His Asn Leu Leu Phe Leu Leu
290           295           300

```

Cys His Leu Thr Ala Met Ile Ser Thr Cys Val Asn Pro Ile Phe Tyr
 305 310 315 320
 Gly Phe Leu Asn Lys Asn Phe Gln Arg Asp Leu Gln Phe Phe Phe Asn
 325 330 335
 Phe Cys Asp Phe Arg Ser Arg Asp Asp Asp Tyr Glu Thr Ile Ala Met
 340 345 350
 Ser Thr Met His Thr Asp Val Ser Lys Thr Ser Leu Lys Gln Ala Ser
 355 360 365
 Pro Val Ala Phe Lys Lys Ile Asn Asn Asn Asp Asp Asn Glu Lys Ile
 370 375 380

<210> 3
 <211> 382
 <212> PRT
 <213> Rattus norvegicus

<400> 3
 Met Asn Ser Thr Leu Phe Ser Arg Val Glu Asn Tyr Ser Val His Tyr
 1 5 10 15
 Asn Val Ser Glu Asn Ser Pro Phe Leu Ala Phe Glu Asn Asp Asp Cys
 20 25 30
 His Leu Pro Leu Ala Val Ile Phe Thr Leu Ala Leu Ala Tyr Gly Ala
 35 40 45
 Val Ile Ile Leu Gly Val Ser Gly Asn Leu Ala Leu Ile Ile Ile Ile
 50 55 60
 Leu Lys Gln Lys Glu Met Arg Asn Val Thr Asn Ile Leu Ile Val Asn
 65 70 75 80
 Leu Ser Phe Ser Asp Leu Leu Val Ala Val Met Cys Leu Pro Phe Thr
 85 90 95
 Phe Val Tyr Thr Leu Met Asp His Trp Val Phe Gly Glu Thr Met Cys
 100 105 110
 Lys Leu Asn Pro Phe Val Gln Cys Val Ser Ile Thr Val Ser Ile Phe
 115 120 125
 Ser Leu Val Leu Ile Ala Val Glu Arg His Gln Leu Ile Ile Asn Pro
 130 135 140
 Arg Gly Trp Arg Pro Asn Asn Arg His Ala Tyr Ile Gly Ile Thr Val
 145 150 155 160
 Ile Trp Val Leu Ala Val Ala Ser Ser Leu Pro Phe Val Ile Tyr Gln

| | | |
|---|-----|-----|
| 165 | 170 | 175 |
| Ile Leu Thr Asp Glu Pro Phe Gln Asn Val Ser Leu Ala Ala Phe Lys | | |
| 180 | 185 | 190 |
| Asp Lys Tyr Val Cys Phe Asp Lys Phe Pro Ser Asp Ser His Arg Leu | | |
| 195 | 200 | 205 |
| Ser Tyr Thr Thr Leu Leu Leu Val Leu Gln Tyr Phe Gly Pro Leu Cys | | |
| 210 | 215 | 220 |
| Phe Ile Phe Ile Cys Tyr Phe Lys Ile Tyr Ile Arg Leu Lys Arg Arg | | |
| 225 | 230 | 235 |
| Asn Asn Met Met Asp Lys Ile Arg Asp Ser Lys Tyr Arg Ser Ser Glu | | |
| 245 | 250 | 255 |
| Thr Lys Arg Ile Asn Val Met Leu Leu Ser Ile Val Val Ala Phe Ala | | |
| 260 | 265 | 270 |
| Val Cys Trp Leu Pro Leu Thr Ile Phe Asn Thr Val Phe Asp Trp Asn | | |
| 275 | 280 | 285 |
| His Gln Ile Ile Ala Thr Cys Asn His Asn Leu Leu Phe Leu Leu Cys | | |
| 290 | 295 | 300 |
| His Leu Thr Ala Met Ile Ser Thr Cys Val Asn Pro Ile Phe Tyr Gly | | |
| 305 | 310 | 315 |
| Phe Leu Asn Lys Asn Phe Gln Arg Asp Leu Gln Phe Phe Phe Asn Phe | | |
| 325 | 330 | 335 |
| Cys Asp Phe Arg Ser Arg Asp Asp Asp Tyr Glu Thr Ile Ala Met Ser | | |
| 340 | 345 | 350 |
| Thr Met His Thr Asp Val Ser Lys Thr Ser Leu Lys Gln Ala Ser Pro | | |
| 355 | 360 | 365 |
| Val Ala Phe Lys Lys Ile Ser Met Asn Asp Asn Glu Lys Ile | | |
| 370 | 375 | 380 |

<210> 4

<211> 1406

<212> DNA

<213> Homo sapiens

<400> 4

```

ttttggttgc tgacaaatgt ctttttattc caagcaggac tataatatgg atttagagct 60
cgacgagtat tataacaaga cacttgccac agagaataat actgctgcc ctcggaattc 120
tgatttccca gtctgggatg actataaaag cagtgtagat gacttacagt attttctgat 180
tgggctctat acatttgtaa gtcttcttgg ctttatgggg aatctactta ttttaatggc 240
tctcatgaaa aagcgtaatc agaagactac ggtaaacttc ctcataggca atctggcctt 300
ttctgatatc ttggttggtg tgttttgctc acctttcaca ctgacgtctg tcttgctgga 360
tcagtggatg tttggcaaag tcatgtgcc ttttatgcct tttcttcaat gtgtgtcagt 420
tttggtttca actttaattt taatatcaat tgccattgtc aggtatcata tgataaaaca 480
tcccatatct aataatttaa cagcaaacca tggctacttt ctgatatgta ctgtctggac 540

```

```

actagggtttt gccatctggt ccccccttcc agtgtttcac agtcttgtgg aacttcaaga 600
aacatttggt tcagcattgc tgagcagcag gtatttatgt gttgagtcac ggccatctga 660
ttcatacaga attgccttta ctatctcttt attgctagtt cagtatatcc tgcccttagt 720
ttgtcttact gtaagtcata caagtgtctg cagaagtata agctgtggat tgtccaacaa 780
agaaaacaga cttgaagaaa atgagatgat caacttaact cttcatccat ccaaaaagag 840
tgggcctcag gtgaaactct ctggcagcca taaatggagt tattcattca tcaaaaaaca 900
cagaagaaga tatagcaaga agacagcatg tgtgttacct gctccagaaa gaccttctca 960
agagaaccac tccagaatac ttccagaaaa ctttggtctt gtaagaagtc agctctcttc 1020
atccagtaag ttcataccag gggctccccac ttgctttgag ataaaacctg aagaaaattc 1080
agatgttcat gaattgagag taaaacgttc tgttacaaga ataaaaaaga gatctcgaag 1140
tgttttctac agactgacca tactgatatt agtatttgct gttagttgga tgccactaca 1200
ccttttccat gtggtaactg attttaatga caatcttatt tcaaataaggc atttcaagtt 1260
gggtgattgc atttgtcatt tgttgggcat gatgtcctgt tgtcttaatc caattctata 1320
tgggtttctt aataatggga ttaaagctga tttagtgtcc cttatacact gtcttcatat 1380
gtaataattc tcactgttta ccaagg                                     1406

```

<210> 5

<211> 1069

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Y5/Y1 CHIMERA

<400> 5

```

ttttggttgc tgacaaatgt ctttttattc caagcaggac tataatatgg atttagagct 60
cgacgagtat tataacaaga cacttgccac agagaataat actgctgcca ctcggaattc 120
tgatttccca gtctgggatg actataaaag cagtgtagat gacttacagt attttctgat 180
tgggctctat acatttgtaa gtcttcttgg ctttatgggg aatctactta ttttaattggc 240
tctcatgaaa aagcgtaatc agaagactac ggtaaacttc ctcataggca atctggcctt 300
ttctgatatc ttggttgtgc tgttttgctc acctttcaca ctgacgtctg tcttgctgga 360
tcagtggatg tttggcaaaag tcatgtgcca tattatgcct tttcttcaat gtgtgtcagt 420
tttggtttca actttaattt taatatcaat tgccattgtc aggtatcata tgataaaaca 480
tcccatactt aataatttaa cagcaaacca tggctacttt ctgatatgta ctgtctggac 540
actaggtttt gccatctggt ccccccttcc agtgtttcac agtcttgtgg aacttcaaga 600
aacatttggt tcagcattgc tgagcagcag gtatttatgt gttgagtcac ggccatctga 660
ttcatacaga attgccttta ctatctcttt attgctagtt cagtatatcc tgcccttagt 720
ttgtcttact gtaagtcata caagtgtctg catagccta aaaaggagaa acaacatgat 780
ggacaagatg agagacaata agtacaggtc cagtagatct cgaagtgttt tctacagact 840
gaccatactg atattagtat ttgctgttag ttggatgcca ctacaccttt tccatgtggt 900
aactgatttt aatgacaatc ttatttcaaa taggcatttc aagttgggtg attgcatttg 960
tcatttggtg ggcattgatg cctgttgtct taatccaatt ctatatgggt ttcttaataa 1020
tgggattaaa gctgatttag tgtcccttat acactgtctt catatgtaa                                     1069

```

<210> 6

<211> 350

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Y5/Y1 CHIMERA

<400> 6

```

Met Ser Phe Tyr Ser Lys Gln Asp Tyr Asn Met Asp Leu Glu Leu Asp
  1              5              10              15

```

Glu Tyr Tyr Asn Lys Thr Leu Ala Thr Glu Asn Asn Thr Ala Ala Thr
 20 25 30
 Arg Asn Ser Asp Phe Pro Val Trp Asp Asp Tyr Lys Ser Ser Val Asp
 35 40 45
 Asp Leu Gln Tyr Phe Leu Ile Gly Leu Tyr Thr Phe Val Ser Leu Leu
 50 55 60
 Gly Phe Met Gly Asn Leu Leu Ile Leu Met Ala Leu Met Lys Lys Arg
 65 70 75 80
 Asn Gln Lys Thr Thr Val Asn Phe Leu Ile Gly Asn Leu Ala Phe Ser
 85 90 95
 Asp Ile Leu Val Val Leu Phe Cys Ser Pro Phe Thr Leu Thr Ser Val
 100 105 110
 Leu Leu Asp Gln Trp Met Phe Gly Lys Val Met Cys His Ile Met Pro
 115 120 125
 Phe Leu Gln Cys Val Ser Val Leu Val Ser Thr Leu Ile Leu Ile Ser
 130 135 140
 Ile Ala Ile Val Arg Tyr His Met Ile Lys His Pro Ile Ser Asn Asn
 145 150 155 160
 Leu Thr Ala Asn His Gly Tyr Phe Leu Ile Ala Thr Val Trp Thr Leu
 165 170 175
 Gly Phe Ala Ile Cys Ser Pro Leu Pro Val Phe His Ser Leu Val Glu
 180 185 190
 Leu Gln Glu Thr Phe Gly Ser Ala Leu Leu Ser Ser Arg Tyr Leu Cys
 195 200 205
 Val Glu Ser Trp Pro Ser Asp Ser Tyr Arg Ile Ala Phe Thr Ile Ser
 210 215 220
 Leu Leu Leu Val Gln Tyr Ile Leu Pro Leu Val Cys Leu Thr Val Ser
 225 230 235 240
 His Thr Ser Val Cys Ile Arg Leu Lys Arg Arg Asn Asn Met Met Asp
 245 250 255
 Lys Met Arg Asp Asn Lys Tyr Arg Ser Ser Arg Ser Arg Ser Val Phe
 260 265 270
 Tyr Arg Leu Thr Ile Leu Ile Leu Val Phe Ala Val Ser Trp Met Pro
 275 280 285
 Leu His Leu Phe His Val Val Thr Asp Phe Asn Asp Asn Leu Ile Ser
 290 295 300
 Asn Arg His Phe Lys Leu Val Tyr Cys Ile Cys His Leu Leu Gly Met
 305 310 315 320

Met Ser Cys Cys Leu Asn Pro Ile Leu Tyr Gly Phe Leu Asn Asn Gly
 325 330 335

Ile Lys Ala Asp Leu Val Ser Leu Ile His Cys Leu His Met
 340 345 350

<210> 7

<211> 1500

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Y5/Y1 CHIMERA

<400> 7

```

atgtcttttt attccaagca ggactataat atggatttag agctcgacga gtattataac 60
aagacacttg ccacagagaa taatactgct gccactcgga attctgattt cccagtctgg 120
gatgactata aaagcagtgat agatgactta cagtattttc tgattgggct ctatacattt 180
gtaagtcttc ttggctttat ggggaatcta cttattttta tggctctcat gaaaaagcgt 240
aatcagaaga ctacggtaaa cttctcataa ggcaatctgg ctttttctga tatcttggtt 300
gtgctgtttt gctcaccttt cacactgacg tctgtcttgc tggatcagtg gatgtttggc 360
aaagtcatgt gccatattat gccttttctt caatgtgtgt cagttttggg ttcaacttta 420
attttaatat caattgccat tgtcaggtat catatgataa aacatcccat atctaataat 480
ttaacagcaa accatggcta ctttctgata gctactgtct ggacactagg ttttgccatc 540
tgttctcccc ttccagtgtt tcacagtctt gtggaacttc aagaaacatt tggttcagca 600
ttgctgagca gcaggtattt atgtgttgag tcattggccat ctgattcata cagaattgcc 660
tttactatct ctttattgct agttcagtat attctgccct tagtttgtct tactgtaagt 720
catacaagtg tctgcagaag tataagctgt ggattgtcca acaaagaaaa cagacttgaa 780
gaaaatgaga tgatcaactt aactcttcat ccattcaaaa agagtgggcc tcaggtgaaa 840
ctctctggca gccataaatg gagttattca ttcattcaaaa aacacagaag aagatatagc 900
aagaagacag catgtgtgtt acctgtctca gaaagacctt ctcaagagaa ccaactccaga 960
atcttccag aaaacttttg ctctgtaaga agtcagctct cttcatccag taagttcata 1020
ccaggggtcc cacttgctt tgagataaaa cctgaagaaa attcagatgt tcatgaattg 1080
agagtaaaac gttctgttac aagaataaaa aagagatctc gaagtgtttt ctacagactg 1140
accatactga tattagtatt tgctgttagt tggatgccac tacacctttt ccatgtggta 1200
actgatttta atgacaatct tatttcaaat aggcatttca agttggtgta ttgcatttgt 1260
cattttgttg gcatgatgtc ctgtgtgtt aatccaattc tatatgggtt tcttaataat 1320
ggaattcaga gagacttgca gttctcttc aacttttgtg atttccggtc tcgggatgat 1380
gattatgaaa caatagccat gtccacgatg cacacagatg tttccaaaac ttctttgaag 1440
caagcaagcc cagtcgcatt taaaaaatc aacaacaatg atgataatga aaaaatctga 1500

```

<210> 8

<211> 1201

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Y5/Y1 CHIMERA

<400> 8

```

ttttggttgc tgacaaatgt ctttttattc caagcaggac tataatatgg atttagagct 60
cgacgagtat tataacaaga cacttgccac agagaataat actgctgcca ctcggaattc 120
tgatttccca gtctgggatg actataaaag cagtgtagat gacttacagt attttctgat 180
tgggtcttat acatttgtaa gtcttcttgg ctttatgggg aatctactta ttttaattgc 240

```

```

tctcatgaaa aagcgtaatc agaagactac ggtaaacttc ctcataggca atctggcctt 300
ttctgataac ttggttggtc tgttttgctc acctttcaca ctgacgtctg tcttgctgga 360
tcagtggatg tttggcaaaag tcatgtgcc aattatgcct tttcttcaat gtgtgtcagt 420
tttggtttca actttaattt taatatcaat tgccattgtc aggtatcata tgataaaaca 480
tcccataatc aataatttaa cagcaaacca tggctacttt ctgatatgta ctgtctggac 540
actaggtttt gccatctgtt ctccccttcc agtgtttcac agtcttgttg aacttcaaga 600
aacatttggg tcagcattgc tgagcagcag gtatttatgt gttgagtcac ggccatctga 660
ttcatacaga attgccttta ctatctcttt attgctagtt cagtatatcc tgcccttagt 720
ttgtcttact gtaagtcata caagtgtctg catacgccta aaaaggagaa acaacatgat 780
ggacaagatg agagacaata agtacaggtc cagtagatct cgaagtgttt tctacagact 840
gaccatactg atattagtat ttgctgttag ttggatgcc aacaccttt tccatgtggt 900
aactgatttt aatgacaatc ttatttcaaa taggcatttc aagttggtgt attgcatttg 960
tcatttggtg ggcattgatg cctgttgtct taatccaatt ctatatgggt ttcttaataa 1020
tggaattcag agagacttgc agttcttctt caacttttgt gatttccggg ctccgggatga 1080
tgattatgaa acaatagcca tgtccacgat gcacacagat gtttccaaaa ctcttttgaa 1140
gcaagcaagc ccagtcgcac ttaaaaaaat caacaacaat gatgataatg aaaaaatctg 1200
a

```

<210> 9

<211> 499

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Y5/Y1 CHIMERA

<400> 9

```

Met Ser Phe Tyr Ser Lys Gln Asp Tyr Asn Met Asp Leu Glu Leu Asp
 1             5             10             15

Glu Tyr Tyr Asn Lys Thr Leu Ala Thr Glu Asn Asn Thr Ala Ala Thr
      20             25             30

Arg Asn Ser Asp Phe Pro Val Trp Asp Asp Tyr Lys Ser Ser Val Asp
      35             40             45

Asp Leu Gln Tyr Phe Leu Ile Gly Leu Tyr Thr Phe Val Ser Leu Leu
      50             55             60

Gly Phe Met Gly Asn Leu Leu Ile Leu Met Ala Leu Met Lys Lys Arg
      65             70             75             80

Asn Gln Lys Thr Thr Val Asn Phe Leu Ile Gly Asn Leu Ala Phe Ser
      85             90             95

Asp Ile Leu Val Val Leu Phe Cys Ser Pro Phe Thr Leu Thr Ser Val
      100             105             110

Leu Leu Asp Gln Trp Met Phe Gly Lys Val Met Cys His Ile Met Pro
      115             120             125

Phe Leu Gln Cys Val Ser Val Leu Val Ser Thr Leu Ile Leu Ile Ser
      130             135             140

Ile Ala Ile Val Arg Tyr His Met Ile Lys His Pro Ile Ser Asn Asn
      145             150             155             160

```

Leu Thr Ala Asn His Gly Tyr Phe Leu Ile Ala Thr Val Trp Thr Leu
 165 170 175
 Gly Phe Ala Ile Cys Ser Pro Leu Pro Val Phe His Ser Leu Val Glu
 180 185 190
 Leu Gln Glu Thr Phe Gly Ser Ala Leu Leu Ser Ser Arg Tyr Leu Cys
 195 200 205
 Val Glu Ser Trp Pro Ser Asp Ser Tyr Arg Ile Ala Phe Thr Ile Ser
 210 215 220
 Leu Leu Leu Val Gln Tyr Ile Leu Pro Leu Val Cys Leu Thr Val Ser
 225 230 235 240
 His Thr Ser Val Cys Arg Ser Ile Ser Cys Gly Leu Ser Asn Lys Glu
 245 250 255
 Asn Arg Leu Glu Glu Asn Glu Met Ile Asn Leu Thr Leu His Pro Ser
 260 265 270
 Lys Lys Ser Gly Pro Gln Val Lys Leu Ser Gly Ser His Lys Trp Ser
 275 280 285
 Tyr Ser Phe Ile Lys Lys His Arg Arg Arg Tyr Ser Lys Lys Thr Ala
 290 295 300
 Cys Val Leu Pro Ala Pro Glu Arg Pro Ser Gln Glu Asn His Ser Arg
 305 310 315 320
 Ile Leu Pro Glu Asn Phe Gly Ser Val Arg Ser Gln Leu Ser Ser Ser
 325 330 335
 Ser Lys Phe Ile Pro Gly Val Pro Thr Cys Phe Glu Ile Lys Pro Glu
 340 345 350
 Glu Asn Ser Asp Val His Glu Leu Arg Val Lys Arg Ser Val Thr Arg
 355 360 365
 Ile Lys Lys Arg Ser Arg Ser Val Phe Tyr Arg Leu Thr Ile Leu Ile
 370 375 380
 Leu Val Phe Ala Val Ser Trp Met Pro Leu His Leu Phe His Val Val
 385 390 395 400
 Thr Asp Phe Asn Asp Asn Leu Ile Ser Asn Arg His Phe Lys Leu Val
 405 410 415
 Tyr Cys Ile Cys His Leu Leu Gly Met Met Ser Cys Cys Leu Asn Pro
 420 425 430
 Ile Leu Tyr Gly Phe Leu Asn Asn Gly Ile Gln Arg Asp Leu Gln Phe
 435 440 445
 Phe Phe Asn Phe Cys Asp Phe Arg Ser Arg Asp Asp Asp Tyr Glu Thr
 450 455 460

Ile Ala Met Ser Thr Met His Thr Asp Val Ser Lys Thr Ser Leu Lys
465 470 475 480

Gln Ala Ser Pro Val Ala Phe Lys Lys Ile Asn Asn Asn Asp Asp Asn
485 490 495

Glu Lys Ile

<210> 10

<211> 394

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Y5/Y1 CHIMERA

<400> 10

Met Ser Phe Tyr Ser Lys Gln Asp Tyr Asn Met Asp Leu Glu Leu Asp
1 5 10 15

Glu Tyr Tyr Asn Lys Thr Leu Ala Thr Glu Asn Asn Thr Ala Ala Thr
20 25 30

Arg Asn Ser Asp Phe Pro Val Trp Asp Asp Tyr Lys Ser Ser Val Asp
35 40 45

Asp Leu Gln Tyr Phe Leu Ile Gly Leu Tyr Thr Phe Val Ser Leu Leu
50 55 60

Gly Phe Met Gly Asn Leu Leu Ile Leu Met Ala Leu Met Lys Lys Arg
65 70 75 80

Asn Gln Lys Thr Thr Val Asn Phe Leu Ile Gly Asn Leu Ala Phe Ser
85 90 95

Asp Ile Leu Val Val Leu Phe Cys Ser Pro Phe Thr Leu Thr Ser Val
100 105 110

Leu Leu Asp Gln Trp Met Phe Gly Lys Val Met Cys His Ile Met Pro
115 120 125

Phe Leu Gln Cys Val Ser Val Leu Val Ser Thr Leu Ile Leu Ile Ser
130 135 140

Ile Ala Ile Val Arg Tyr His Met Ile Lys His Pro Ile Ser Asn Asn
145 150 155 160

Leu Thr Ala Asn His Gly Tyr Phe Leu Ile Ala Thr Val Trp Thr Leu
165 170 175

Gly Phe Ala Ile Cys Ser Pro Leu Pro Val Phe His Ser Leu Val Glu
180 185 190

Leu Gln Glu Thr Phe Gly Ser Ala Leu Leu Ser Ser Arg Tyr Leu Cys

| 195 | 200 | 205 |
|--|--|---------|
| Val Glu Ser Trp Pro Ser Asp 210 | Ser Tyr Arg Ile Ala Phe Thr Ile Ser 215 | |
| Leu Leu Leu Val Gln Tyr Ile Leu Pro Leu Val Cys Leu Thr Val Ser 225 | | 235 240 |
| His Thr Ser Val Cys Ile Arg Leu Lys Arg Arg Asn Asn Met Met Asp 245 | 250 | 255 |
| Lys Met Arg Asp Asn Lys Tyr Arg Ser Ser Arg Ser Arg Ser Val Phe 260 | 265 | 270 |
| Tyr Arg Leu Thr Ile Leu Ile Leu Val Phe Ala Val Ser Trp Met Pro 275 | 280 | 285 |
| Leu His Leu Phe His Val Val Thr Asp Phe Asn Asp Asn Leu Ile Ser 290 | 295 | 300 |
| Asn Arg His Phe Lys Leu Val Tyr Cys Ile Cys His Leu Leu Gly Met 305 | 310 | 315 320 |
| Met Ser Cys Cys Leu Asn Pro Ile Leu Tyr Gly Phe Leu Asn Asn Gly 325 | 330 | 335 |
| Ile Gln Arg Asp Leu Gln Phe Phe Phe Asn Phe Cys Asp Phe Arg Ser 340 | 345 | 350 |
| Arg Asp Asp Asp Tyr Glu Thr Ile Ala Met Ser Thr Met His Thr Asp 355 | 360 | 365 |
| Val Ser Lys Thr Ser Leu Lys Gln Ala Ser Pro Val Ala Phe Lys Lys 370 | 375 | 380 |
| Ile Asn Asn Asn Asp Asp Asn Glu Lys Ile 385 | 390 | |

<210> 11

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:HEXAHISTADINE
TAG

<400> 11

His His His His His His
1 5

<210> 12

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: FLAG EPITOPE
TAG

<400> 12

Asp Tyr Lys Asp Asp Asp Asp Lys
1 5

<210> 13

<211> 455

<212> PRT

<213> Homo sapiens

<400> 13

Met Ser Phe Tyr Ser Lys Gln Asp Tyr Asn Met Asp Leu Glu Leu Asp
1 5 10 15Glu Tyr Tyr Asn Lys Thr Leu Ala Thr Glu Asn Asn Thr Ala Ala Thr
20 25 30Arg Asn Ser Asp Phe Pro Val Trp Asp Asp Tyr Lys Ser Ser Val Asp
35 40 45Asp Leu Gln Tyr Phe Leu Ile Gly Leu Tyr Thr Phe Val Ser Leu Leu
50 55 60Gly Phe Met Gly Asn Leu Leu Ile Leu Met Ala Leu Met Lys Lys Arg
65 70 75 80Asn Gln Lys Thr Thr Val Asn Phe Leu Ile Gly Asn Leu Ala Phe Ser
85 90 95Asp Ile Leu Val Val Leu Phe Cys Ser Pro Phe Thr Leu Thr Ser Val
100 105 110Leu Leu Asp Gln Trp Met Phe Gly Lys Val Met Cys His Ile Met Pro
115 120 125Phe Leu Gln Cys Val Ser Val Leu Val Ser Thr Leu Ile Leu Ile Ser
130 135 140Ile Ala Ile Val Arg Tyr His Met Ile Lys His Pro Ile Ser Asn Asn
145 150 155 160Leu Thr Ala Asn His Gly Tyr Phe Leu Ile Ala Thr Val Trp Thr Leu
165 170 175Gly Phe Ala Ile Cys Ser Pro Leu Pro Val Phe His Ser Leu Val Glu
180 185 190Leu Gln Glu Thr Phe Gly Ser Ala Leu Leu Ser Ser Arg Tyr Leu Cys
195 200 205Val Glu Ser Trp Pro Ser Asp Ser Tyr Arg Ile Ala Phe Thr Ile Ser
210 215 220

Leu Leu Leu Val Gln Tyr Ile Leu Pro Leu Val Cys Leu Thr Val Ser
 225 230 235 240
 His Thr Ser Val Cys Arg Ser Ile Ser Cys Gly Leu Ser Asn Lys Glu
 245 250 255
 Asn Arg Leu Glu Glu Asn Glu Met Ile Asn Leu Thr Leu His Pro Ser
 260 265 270
 Lys Lys Ser Gly Pro Gln Val Lys Leu Ser Gly Ser His Lys Trp Ser
 275 280 285
 Tyr Ser Phe Ile Lys Lys His Arg Arg Arg Tyr Ser Lys Lys Thr Ala
 290 295 300
 Cys Val Leu Pro Ala Pro Glu Arg Pro Ser Gln Glu Asn His Ser Arg
 305 310 315 320
 Ile Leu Pro Glu Asn Phe Gly Ser Val Arg Ser Gln Leu Ser Ser Ser
 325 330 335
 Ser Lys Phe Ile Pro Gly Val Pro Thr Cys Phe Glu Ile Lys Pro Glu
 340 345 350
 Glu Asn Ser Asp Val His Glu Leu Arg Val Lys Arg Ser Val Thr Arg
 355 360 365
 Ile Lys Lys Arg Ser Arg Ser Val Phe Tyr Arg Leu Thr Ile Leu Ile
 370 375 380
 Leu Val Phe Ala Val Ser Trp Met Pro Leu His Leu Phe His Val Val
 385 390 395 400
 Thr Asp Phe Asn Asp Asn Leu Ile Ser Asn Arg His Phe Lys Leu Val
 405 410 415
 Tyr Cys Ile Cys His Leu Leu Gly Met Met Ser Cys Cys Leu Asn Pro
 420 425 430
 Ile Leu Tyr Gly Phe Leu Asn Asn Gly Ile Lys Ala Asp Leu Val Ser
 435 440 445
 Leu Ile His Cys Leu His Met
 450 455

<210> 14

<211> 21

<212> DNA

<213> Homo sapiens

<400> 14

ttttggttgc tgacaaatgt c

21

<210> 15

<211> 26
<212> DNA
<213> Homo sapiens

<400> 15
ccttggtaaa cagtgagaat tattac

26

<210> 16
<211> 63
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:CHIMERIC Y1/Y5
PRIMER

<400> 16
tacgcctaaa aaggagaaac aacatgatgg acaagatgag agacaataag tacaggtcca 60
gta 63

<210> 17
<211> 71
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:CHIMERIC Y1/Y5
PRIMER

<400> 17
gatctactgg acctgtactt attgtctctc atcttgcca tcatgttggt tctccttttt 60
aggcgatgc a 71

<210> 18
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MUTAGENIC R1
PRIMER

<400> 18
gaacaaaaga attcagagag acttgcagtt c

31

<210> 19
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MUTAGENIC R1
PRIMER

<400> 19
cagcttgaat tccattatta agaaaccc

28

<210> 20
<211> 341
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Y1/Y5 CHIMERA

<400> 20
Met Asp Leu Glu Leu Gln Asp Phe Tyr Asn Lys Thr Leu Ala Thr Glu
1 5 10 15
Asn Asn Thr Ala Ala Thr Arg Asn Ser Asp Phe Pro Val Trp Asp Asp
20 25 30
Tyr Lys Ser Ser Val Asp Asp Leu Gln Tyr Phe Leu Ile Gly Leu Tyr
35 40 45
Thr Phe Val Ser Leu Leu Gly Phe Met Gly Asn Leu Leu Ile Leu Met
50 55 60
Ala Leu Met Arg Lys Arg Asn Gln Lys Thr Met Val Asn Phe Leu Ile
65 70 75 80
Gly Asn Leu Ala Phe Ser Asp Ile Leu Val Val Leu Phe Cys Ser Pro
85 90 95
Phe Thr Leu Thr Ser Val Leu Leu Asp Gln Trp Met Phe Gly Lys Val
100 105 110
Met Cys His Ile Met Pro Phe Leu Gln Cys Val Ser Val Leu Val Ser
115 120 125
Thr Leu Ile Leu Ile Ser Ile Ala Ile Val Arg Tyr His Met Ile Lys
130 135 140
His Pro Ile Ser Asn Asn Leu Thr Ala Asn His Gly Tyr Phe Leu Ile
145 150 155 160
Ala Thr Val Trp Thr Leu Gly Phe Ala Ile Cys Ser Pro Leu Pro Val
165 170 175
Phe His Ser Leu Val Glu Leu Gln Glu Thr Phe Asp Ser Ala Leu Leu
180 185 190
Ser Ser Arg Tyr Leu Cys Val Glu Ser Trp Pro Ser Asp Ser Tyr Arg
195 200 205
Ile Ala Phe Thr Ile Ser Leu Leu Leu Val Gln Tyr Ile Leu Pro Leu
210 215 220
Val Cys Leu Thr Val Ser His Thr Ser Val Cys Ile Arg Leu Lys Arg

225 230 235 240
 Arg Asn Asn Met Met Asp Lys Met Arg Asp Asn Lys Tyr Arg Ser Ser
 245 250 255
 Arg Ser Arg Ser Val Phe Tyr Arg Leu Thr Ile Leu Ile Leu Val Phe
 260 265 270
 Ala Val Ser Trp Met Pro Leu His Leu Phe His Val Val Thr Asp Phe
 275 280 285
 Asn Asp Asn Leu Ile Ser Asn Arg His Phe Lys Leu Val Tyr Cys Ile
 290 295 300
 Cys His Leu Leu Gly Met Met Ser Cys Cys Leu Asn Pro Ile Leu Tyr
 305 310 315 320
 Gly Phe Leu Asn Asn Gly Ile Lys Ala Asp Leu Ile Ser Leu Ile Gln
 325 330 335
 Cys Leu His Met Ser
 340

<210> 21
 <211> 383
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:Y1/Y5 CHIMERA

<400> 21
 Met Asp Leu Glu Leu Gln Asp Phe Tyr Asn Lys Thr Leu Ala Thr Glu
 1 5 10 15
 Asn Asn Thr Ala Ala Thr Arg Asn Ser Asp Phe Pro Val Trp Asp Asp
 20 25 30
 Tyr Lys Ser Ser Val Asp Asp Leu Gln Tyr Phe Leu Ile Gly Leu Tyr
 35 40 45
 Thr Phe Val Ser Leu Leu Gly Phe Met Gly Asn Leu Leu Ile Leu Met
 50 55 60
 Ala Leu Met Arg Lys Arg Asn Gln Lys Thr Met Val Asn Phe Leu Ile
 65 70 75 80
 Gly Asn Leu Ala Phe Ser Asp Ile Leu Val Val Leu Phe Cys Ser Pro
 85 90 95
 Phe Thr Leu Thr Ser Val Leu Leu Asp Gln Trp Met Phe Gly Lys Val
 100 105 110
 Met Cys His Ile Met Pro Phe Leu Gln Cys Val Ser Val Leu Val Ser
 115 120 125

Thr Leu Ile Leu Ile Ser Ile Ala Ile Val Arg Tyr His Met Ile Lys
 130 135 140
 His Pro Ile Ser Asn Asn Leu Thr Ala Asn His Gly Tyr Phe Leu Ile
 145 150 155 160
 Ala Thr Val Trp Thr Leu Gly Phe Ala Ile Cys Ser Pro Leu Pro Val
 165 170 175
 Phe His Ser Leu Val Glu Leu Gln Glu Thr Phe Asp Ser Ala Leu Leu
 180 185 190
 Ser Ser Arg Tyr Leu Cys Val Glu Ser Trp Pro Ser Asp Ser Tyr Arg
 195 200 205
 Ile Ala Phe Thr Ile Ser Leu Leu Leu Val Gln Tyr Ile Leu Pro Leu
 210 215 220
 Val Cys Leu Thr Val Ser His Thr Ser Val Cys Ile Arg Leu Lys Arg
 225 230 235 240
 Arg Asn Asn Met Met Asp Lys Met Arg Asp Asn Lys Tyr Arg Ser Ser
 245 250 255
 Arg Ser Arg Ser Val Phe Tyr Arg Leu Thr Ile Leu Ile Leu Val Phe
 260 265 270
 Ala Val Ser Trp Met Pro Leu His Leu Phe His Val Val Thr Asp Phe
 275 280 285
 Asn Asp Asn Leu Ile Ser Asn Arg His Phe Lys Leu Val Tyr Cys Ile
 290 295 300
 Cys His Leu Leu Gly Met Met Ser Cys Cys Leu Asn Pro Ile Leu Tyr
 305 310 315 320
 Gly Phe Leu Asn Asn Gly Ile Gln Arg Asp Leu Gln Phe Phe Phe Asn
 325 330 335
 Phe Cys Asp Phe Arg Ser Arg Asp Asp Asp Tyr Glu Thr Ile Ala Met
 340 345 350
 Ser Thr Met His Thr Asp Val Ser Lys Thr Ser Leu Lys Gln Ala Ser
 355 360 365
 Pro Val Ala Phe Lys Lys Ile Asn Asn Asp Asp Asn Glu Lys Ile
 370 375 380

<210> 22

<211> 508

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Y1/Y5 CHIMERA

<400> 22

Met Glu Val Lys Leu Glu Glu His Phe Asn Lys Thr Phe Val Thr Glu
 1 5 10 15
 Asn Asn Thr Ala Ala Ser Gln Asn Thr Ala Ser Pro Ala Trp Glu Asp
 20 25 30
 Tyr Arg Gly Thr Glu Asn Asn Thr Ser Ala Ala Arg Asn Thr Ala Phe
 35 40 45
 Pro Val Trp Glu Asp Tyr Arg Gly Ser Val Asp Asp Leu Gln Tyr Phe
 50 55 60
 Leu Ile Gly Leu Tyr Thr Phe Val Ser Leu Leu Gly Phe Met Gly Asn
 65 70 75 80
 Leu Leu Ile Leu Met Ala Val Met Lys Lys Arg Asn Gln Lys Thr Thr
 85 90 95
 Val Asn Phe Leu Ile Gly Asn Leu Ala Phe Ser Asp Ile Leu Val Val
 100 105 110
 Leu Phe Cys Ser Pro Phe Thr Leu Thr Ser Val Leu Leu Asp Gln Trp
 115 120 125
 Met Phe Gly Lys Ala Met Cys His Ile Met Pro Phe Leu Gln Cys Val
 130 135 140
 Ser Val Leu Val Ser Thr Leu Ile Leu Ile Ser Ile Ala Ile Val Arg
 145 150 155 160
 Tyr His Met Ile Lys His Pro Ile Ser Asn Asn Leu Thr Ala Asn His
 165 170 175
 Gly Tyr Phe Leu Ile Ala Thr Val Trp Thr Leu Gly Phe Ala Ile Cys
 180 185 190
 Ser Pro Phe Pro Val Phe His Ser Leu Val Glu Leu Lys Glu Thr Phe
 195 200 205
 Gly Ser Ala Leu Leu Ser Ser Lys Tyr Leu Cys Val Glu Ser Trp Pro
 210 215 220
 Ser Asp Ser Tyr Arg Ile Ala Phe Thr Ile Ser Leu Leu Leu Val Gln
 225 230 235 240
 Tyr Ile Leu Pro Leu Val Cys Leu Thr Val Ser His Thr Ser Val Cys
 245 250 255
 Arg Ser Ile Ser Cys Gly Leu Ser His Lys Glu Asn Arg Leu Glu Glu
 260 265 270
 Asn Glu Met Ile Asn Leu Thr Leu His Pro Ser Lys Lys Ser Arg Asp
 275 280 285
 Gln Ala Lys Pro Pro Ser Thr Gln Lys Trp Ser Tyr Ser Phe Ile Arg
 290 295 300

Lys His Arg Arg Arg Tyr Ser Lys Lys Thr Ala Cys Val Leu Pro Ala
 305 310 315 320
 Pro Ala Gly Pro Ser Gln Glu Lys His Leu Thr Val Pro Glu Asn Pro
 325 330 335
 Gly Ser Val Arg Ser Gln Leu Ser Pro Ser Ser Lys Val Ile Pro Gly
 340 345 350
 Val Pro Ile Cys Phe Glu Val Lys Pro Glu Glu Ser Ser Asp Ala Gln
 355 360 365
 Glu Met Arg Val Lys Arg Ser Leu Thr Arg Ile Lys Lys Arg Ser Arg
 370 375 380
 Ser Val Phe Tyr Arg Leu Thr Ile Leu Ile Leu Val Phe Ala Val Ser
 385 390 395 400
 Trp Met Pro Leu His Val Phe His Val Val Thr Asp Phe Asn Asp Asn
 405 410 415
 Leu Ile Ser Asn Arg His Phe Lys Leu Val Tyr Cys Ile Cys His Leu
 420 425 430
 Leu Gly Met Met Ser Cys Cys Leu Asn Pro Ile Leu Tyr Gly Phe Leu
 435 440 445
 Asn Asn Gly Ile Gln Arg Asp Leu Gln Phe Phe Phe Asn Phe Cys Asp
 450 455 460
 Phe Arg Ser Arg Asp Asp Asp Tyr Glu Thr Ile Ala Met Ser Thr Met
 465 470 475 480
 His Thr Asp Val Ser Lys Thr Ser Leu Lys Gln Ala Ser Pro Val Ala
 485 490 495
 Phe Lys Lys Ile Ser Met Asn Asp Asn Glu Lys Val
 500 505

<210> 23

<211> 352

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Y1/Y5 CHIMERA

<400> 23

Met Asp Val Leu Phe Phe His Gln Asp Ser Ser Met Glu Phe Lys Leu
 1 5 10 15

Glu Glu His Phe Asn Lys Thr Phe Val Thr Glu Asn Asn Thr Ala Ala
 20 25 30

Ala Arg Asn Ala Ala Phe Pro Ala Trp Glu Asp Tyr Arg Gly Ser Val

| 35 | | | | | 40 | | | | | 45 | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Asp | Leu | Gln | Tyr | Phe | Leu | Ile | Gly | Leu | Tyr | Thr | Phe | Val | Ser | Leu |
| 50 | | | | | 55 | | | | | 60 | | | | | |
| Leu | Gly | Phe | Met | Gly | Asn | Leu | Leu | Ile | Leu | Met | Ala | Val | Met | Lys | Lys |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 |
| Arg | Asn | Gln | Lys | Thr | Thr | Val | Asn | Phe | Leu | Ile | Gly | Asn | Leu | Ala | Phe |
| | | | | 85 | | | | | 90 | | | | | 95 | |
| Ser | Asp | Ile | Leu | Val | Val | Leu | Phe | Cys | Ser | Pro | Phe | Thr | Leu | Thr | Ser |
| | | | 100 | | | | | 105 | | | | | 110 | | |
| Val | Leu | Leu | Asp | Gln | Trp | Met | Phe | Gly | Lys | Ala | Met | Cys | His | Ile | Met |
| | | | 115 | | | | | 120 | | | | | 125 | | |
| Pro | Phe | Leu | Gln | Cys | Val | Ser | Val | Leu | Val | Ser | Thr | Leu | Ile | Leu | Ile |
| | | | 130 | | | | | 135 | | | | | 140 | | |
| Ser | Ile | Ala | Ile | Val | Arg | Tyr | His | Met | Ile | Lys | His | Pro | Ile | Ser | Asn |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 |
| Asn | Leu | Thr | Ala | Asn | His | Gly | Tyr | Phe | Leu | Ile | Ala | Thr | Val | Trp | Thr |
| | | | | 165 | | | | | 170 | | | | | 175 | |
| Leu | Gly | Phe | Ala | Ile | Cys | Ser | Pro | Leu | Pro | Val | Phe | His | Ser | Leu | Val |
| | | | 180 | | | | | 185 | | | | | 190 | | |
| Glu | Leu | Lys | Glu | Thr | Phe | Gly | Ser | Ala | Leu | Leu | Ser | Ser | Lys | Tyr | Leu |
| | | | 195 | | | | | 200 | | | | | 205 | | |
| Cys | Val | Glu | Ser | Trp | Pro | Ser | Asp | Ser | Tyr | Arg | Ile | Ala | Phe | Thr | Ile |
| | | | 210 | | | | | 215 | | | | | 220 | | |
| Ser | Leu | Leu | Leu | Val | Gln | Tyr | Ile | Leu | Pro | Leu | Val | Cys | Leu | Thr | Val |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 |
| Ser | His | Thr | Ser | Val | Cys | Ile | Arg | Leu | Lys | Arg | Arg | Asn | Asn | Met | Met |
| | | | | 245 | | | | | 250 | | | | | 255 | |
| Asp | Lys | Ile | Arg | Asp | Ser | Lys | Tyr | Arg | Ser | Ser | Arg | Ser | Arg | Ser | Val |
| | | | 260 | | | | | 265 | | | | | | 270 | |
| Phe | Tyr | Arg | Leu | Thr | Ile | Leu | Ile | Leu | Val | Phe | Ala | Val | Ser | Trp | Met |
| | | | 275 | | | | | 280 | | | | | 285 | | |
| Pro | Leu | His | Val | Phe | His | Val | Val | Thr | Asp | Phe | Asn | Asp | Asn | Leu | Ile |
| | | | 290 | | | | | 295 | | | | | 300 | | |
| Ser | Asn | Arg | His | Phe | Lys | Leu | Val | Tyr | Cys | Ile | Cys | His | Leu | Leu | Gly |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 |
| Met | Met | Ser | Cys | Cys | Leu | Asn | Pro | Ile | Leu | Tyr | Gly | Phe | Leu | Asn | Asn |
| | | | | 325 | | | | | 330 | | | | | 335 | |
| Gly | Ile | Lys | Ala | Asp | Leu | Arg | Ala | Leu | Ile | His | Cys | Leu | His | Met | Ser |

340

345

350

<210> 24

<211> 499

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Y1/Y5 CHIMERA

<400> 24

Met Asp Val Leu Phe Phe His Gln Asp Ser Ser Met Glu Phe Lys Leu
 1 5 10 15

Glu Glu His Phe Asn Lys Thr Phe Val Thr Glu Asn Asn Thr Ala Ala
 20 25 30

Ala Arg Asn Ala Ala Phe Pro Ala Trp Glu Asp Tyr Arg Gly Ser Val
 35 40 45

Asp Asp Leu Gln Tyr Phe Leu Ile Gly Leu Tyr Thr Phe Val Ser Leu
 50 55 60

Leu Gly Phe Met Gly Asn Leu Leu Ile Leu Met Ala Val Met Lys Lys
 65 70 75 80

Arg Asn Gln Lys Thr Thr Val Asn Phe Leu Ile Gly Asn Leu Ala Phe
 85 90 95

Ser Asp Ile Leu Val Val Leu Phe Cys Ser Pro Phe Thr Leu Thr Ser
 100 105 110

Val Leu Leu Asp Gln Trp Met Phe Gly Lys Ala Met Cys His Ile Met
 115 120 125

Pro Phe Leu Gln Cys Val Ser Val Leu Val Ser Thr Leu Ile Leu Ile
 130 135 140

Ser Ile Ala Ile Val Arg Tyr His Met Ile Lys His Pro Ile Ser Asn
 145 150 155 160

Asn Leu Thr Ala Asn His Gly Tyr Phe Leu Ile Ala Thr Val Trp Thr
 165 170 175

Leu Gly Phe Ala Ile Cys Ser Pro Leu Pro Val Phe His Ser Leu Val
 180 185 190

Glu Leu Lys Glu Thr Phe Gly Ser Ala Leu Leu Ser Ser Lys Tyr Leu
 195 200 205

Cys Val Glu Ser Trp Pro Ser Asp Ser Tyr Arg Ile Ala Phe Thr Ile
 210 215 220

Ser Leu Leu Leu Val Gln Tyr Ile Leu Pro Leu Val Cys Leu Thr Val
 225 230 235 240
 Ser His Thr Ser Val Cys Arg Ser Ile Ser Cys Gly Leu Ser His Lys
 245 250 255
 Glu Asn Arg Leu Glu Glu Asn Glu Met Ile Asn Leu Thr Leu Gln Pro
 260 265 270
 Ser Lys Lys Ser Arg Asn Gln Ala Lys Thr Pro Ser Thr Gln Lys Trp
 275 280 285
 Ser Tyr Ser Phe Ile Arg Lys His Arg Arg Arg Tyr Ser Lys Lys Thr
 290 295 300
 Ala Cys Val Leu Pro Ala Pro Ala Gly Pro Ser Gln Gly Lys His Leu
 305 310 315 320
 Ala Val Pro Glu Asn Pro Ala Ser Val Arg Ser Gln Leu Ser Pro Ser
 325 330 335
 Ser Lys Val Ile Pro Gly Val Pro Ile Cys Phe Glu Val Lys Pro Glu
 340 345 350
 Glu Ser Ser Asp Ala His Glu Met Arg Val Lys Arg Ser Ile Thr Arg
 355 360 365
 Ile Lys Lys Arg Ser Arg Ser Val Phe Tyr Arg Leu Thr Ile Leu Ile
 370 375 380
 Leu Val Phe Ala Val Ser Trp Met Pro Leu His Val Phe His Val Val
 385 390 395 400
 Thr Asp Phe Asn Asp Asn Leu Ile Ser Asn Arg His Phe Lys Leu Val
 405 410 415
 Tyr Cys Ile Cys His Leu Leu Gly Met Met Ser Cys Cys Leu Asn Pro
 420 425 430
 Ile Leu Tyr Gly Phe Leu Asn Asn Gly Ile Lys Gln Arg Asp Leu Gln
 435 440 445
 Phe Phe Phe Asn Phe Cys Asp Phe Arg Ser Arg Asp Asp Asp Tyr Glu
 450 455 460
 Thr Ile Ala Met Ser Thr Met His Thr Asp Val Ser Lys Thr Ser Leu
 465 470 475 480
 Lys Gln Ala Ser Pro Val Ala Phe Lys Lys Ile Ser Met Asn Asp Asn
 485 490 495
 Glu Lys Ile

<210> 25

<211> 395

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Y1/Y5 CHIMERA

<400> 25

Met Asp Val Leu Phe Phe His Gln Asp Ser Ser Met Glu Phe Lys Leu
 1 5 10 15

Glu Glu His Phe Asn Lys Thr Phe Val Thr Glu Asn Asn Thr Ala Ala
 20 25 30

Ala Arg Asn Ala Ala Phe Pro Ala Trp Glu Asp Tyr Arg Gly Ser Val
 35 40 45

Asp Asp Leu Gln Tyr Phe Leu Ile Gly Leu Tyr Thr Phe Val Ser Leu
 50 55 60

Leu Gly Phe Met Gly Asn Leu Leu Ile Leu Met Ala Val Met Lys Lys
 65 70 75 80

Arg Asn Gln Lys Thr Thr Val Asn Phe Leu Ile Gly Asn Leu Ala Phe
 85 90 95

Ser Asp Ile Leu Val Val Leu Phe Cys Ser Pro Phe Thr Leu Thr Ser
 100 105 110

Val Leu Leu Asp Gln Trp Met Phe Gly Lys Ala Met Cys His Ile Met
 115 120 125

Pro Phe Leu Gln Cys Val Ser Val Leu Val Ser Thr Leu Ile Leu Ile
 130 135 140

Ser Ile Ala Ile Val Arg Tyr His Met Ile Lys His Pro Ile Ser Asn
 145 150 155 160

Asn Leu Thr Ala Asn His Gly Tyr Phe Leu Ile Ala Thr Val Trp Thr
 165 170 175

Leu Gly Phe Ala Ile Cys Ser Pro Leu Pro Val Phe His Ser Leu Val
 180 185 190

Glu Leu Lys Glu Thr Phe Gly Ser Ala Leu Leu Ser Ser Lys Tyr Leu
 195 200 205

Cys Val Glu Ser Trp Pro Ser Asp Ser Tyr Arg Ile Ala Phe Thr Ile
 210 215 220

Ser Leu Leu Leu Val Gln Tyr Ile Leu Pro Leu Val Cys Leu Thr Val
 225 230 235 240

Ser His Thr Ser Val Cys Ile Arg Leu Lys Arg Arg Asn Asn Met Met
 245 250 255

Asp Lys Ile Arg Asp Ser Lys Tyr Arg Ser Ser Arg Ser Arg Ser Val
 260 265 270

Phe Tyr Arg Leu Thr Ile Leu Ile Leu Val Phe Ala Val Ser Trp Met
 275 280 285
 Pro Leu His Val Phe His Val Val Thr Asp Phe Asn Asp Asn Leu Ile
 290 295 300
 Ser Asn Arg His Phe Lys Leu Val Tyr Cys Ile Cys His Leu Leu Gly
 305 310 315 320
 Met Met Ser Cys Cys Leu Asn Pro Ile Leu Tyr Gly Phe Leu Asn Asn
 325 330 335
 Gly Ile Lys Gln Arg Asp Leu Gln Phe Phe Phe Asn Phe Cys Asp Phe
 340 345 350
 Arg Ser Arg Asp Asp Asp Tyr Glu Thr Ile Ala Met Ser Thr Met His
 355 360 365
 Thr Asp Val Ser Lys Thr Ser Leu Lys Gln Ala Ser Pro Val Ala Phe
 370 375 380
 Lys Lys Ile Ser Met Asn Asp Asn Glu Lys Ile
 385 390 395

<210> 26
 <211> 341
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:Y1/Y5 CHIMERA

<400> 26
 Met Gly Ser Glu Ile Pro Asp Tyr Tyr Asn Lys Thr Leu Ala Ser Glu
 1 5 10 15
 Asn Asn Thr Val Ala Thr Arg Asn Ser Gly Phe Pro Val Trp Glu Asp
 20 25 30
 Tyr Lys Gly Ser Val Asp Asp Leu Gln Tyr Phe Leu Ile Gly Leu Tyr
 35 40 45
 Thr Phe Val Ser Leu Leu Gly Phe Met Gly Asn Leu Leu Ile Leu Met
 50 55 60
 Ala Val Met Arg Lys Arg Asn Gln Lys Thr Thr Val Asn Phe Leu Ile
 65 70 75 80
 Gly Asn Leu Ala Phe Ser Asp Ile Leu Val Val Leu Phe Cys Ser Pro
 85 90 95
 Phe Thr Leu Thr Ser Val Leu Leu Asp Gln Trp Met Phe Gly Lys Val
 100 105 110
 Met Cys His Ile Met Pro Phe Leu Gln Cys Val Thr Val Leu Val Ser

| | | | | | | | | | | | | | | | |
|--|-----|-----|--|--|--|--|--|--|--|--|--|--|--|--|--|
| 115 | 120 | 125 | | | | | | | | | | | | | |
| Thr Leu Ile Leu Ile Ser Ile Ala Ile Val Arg Tyr His Met Ile Lys 130 135 140 | | | | | | | | | | | | | | | |
| His Pro Val Ser Asn Asn Leu Thr Ala Asn His Gly Tyr Phe Leu Ile 145 150 155 160 | | | | | | | | | | | | | | | |
| Ala Thr Val Trp Thr Leu Gly Leu Ala Ile Cys Ser Pro Leu Pro Val 165 170 175 | | | | | | | | | | | | | | | |
| Phe His Ser Leu Val Glu Leu Gln Glu Ser Phe Gly Ser Ala Trp Leu 180 185 190 | | | | | | | | | | | | | | | |
| Ser Ser Arg Tyr Leu Cys Val Glu Ser Trp Pro Ser Asp Ser Tyr Arg 195 200 205 | | | | | | | | | | | | | | | |
| Ile Ala Phe Thr Ile Ser Leu Leu Leu Val Gln Tyr Ile Leu Pro Leu 210 215 220 | | | | | | | | | | | | | | | |
| Val Cys Leu Thr Val Ser His Thr Ser Val Cys Ile Arg Leu Lys Arg 225 230 235 240 | | | | | | | | | | | | | | | |
| Arg Asn Asn Met Met Asp Lys Met Arg Asp Asn Lys Tyr Arg Ser Ser 245 250 255 | | | | | | | | | | | | | | | |
| Arg Ser Arg Ser Val Phe Tyr Arg Leu Thr Val Leu Ile Leu Val Phe 260 265 270 | | | | | | | | | | | | | | | |
| Ala Val Ser Trp Met Pro Leu His Leu Phe His Val Val Thr Asp Phe 275 280 285 | | | | | | | | | | | | | | | |
| Asn Asp Asn Leu Ile Ser Asn Arg His Phe Lys Leu Val Tyr Cys Ile 290 295 300 | | | | | | | | | | | | | | | |
| Cys His Leu Leu Gly Met Met Ser Cys Cys Leu Asn Pro Ile Leu Tyr 305 310 315 320 | | | | | | | | | | | | | | | |
| Gly Phe Leu Asn Asn Gly Ile Lys Ala Asp Leu Met Ser Leu Ile His 325 330 335 | | | | | | | | | | | | | | | |
| Cys Leu His Val Ser 340 | | | | | | | | | | | | | | | |

<210> 27

<211> 383

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Y1/Y5 CHIMERA

<400> 27

Met Gly Ser Glu Ile Pro Asp Tyr Tyr Asn Lys Thr Leu Ala Ser Glu
1 5 10 15

Asn Asn Thr Val Ala Thr Arg Asn Ser Gly Phe Pro Val Trp Glu Asp
 20 25 30
 Tyr Lys Gly Ser Val Asp Asp Leu Gln Tyr Phe Leu Ile Gly Leu Tyr
 35 40 45
 Thr Phe Val Ser Leu Leu Gly Phe Met Gly Asn Leu Leu Ile Leu Met
 50 55 60
 Ala Val Met Arg Lys Arg Asn Gln Lys Thr Thr Val Asn Phe Leu Ile
 65 70 75 80
 Gly Asn Leu Ala Phe Ser Asp Ile Leu Val Val Leu Phe Cys Ser Pro
 85 90 95
 Phe Thr Leu Thr Ser Val Leu Leu Asp Gln Trp Met Phe Gly Lys Val
 100 105 110
 Met Cys His Ile Met Pro Phe Leu Gln Cys Val Thr Val Leu Val Ser
 115 120 125
 Thr Leu Ile Leu Ile Ser Ile Ala Ile Val Arg Tyr His Met Ile Lys
 130 135 140
 His Pro Val Ser Asn Asn Leu Thr Ala Asn His Gly Tyr Phe Leu Ile
 145 150 155 160
 Ala Thr Val Trp Thr Leu Gly Leu Ala Ile Cys Ser Pro Leu Pro Val
 165 170 175
 Phe His Ser Leu Val Glu Leu Gln Glu Ser Phe Gly Ser Ala Trp Leu
 180 185 190
 Ser Ser Arg Tyr Leu Cys Val Glu Ser Trp Pro Ser Asp Ser Tyr Arg
 195 200 205
 Ile Ala Phe Thr Ile Ser Leu Leu Val Gln Tyr Ile Leu Pro Leu
 210 215 220
 Val Cys Leu Thr Val Ser His Thr Ser Val Cys Ile Arg Leu Lys Arg
 225 230 235 240
 Arg Asn Asn Met Met Asp Lys Met Arg Asp Asn Lys Tyr Arg Ser Ser
 245 250 255
 Arg Ser Arg Ser Val Phe Tyr Arg Leu Thr Val Leu Ile Leu Val Phe
 260 265 270
 Ala Val Ser Trp Met Pro Leu His Leu Phe His Val Val Thr Asp Phe
 275 280 285
 Asn Asp Asn Leu Ile Ser Asn Arg His Phe Lys Leu Val Tyr Cys Ile
 290 295 300
 Cys His Leu Leu Gly Met Met Ser Cys Cys Leu Asn Pro Ile Leu Tyr
 305 310 315 320

<400> 28
ttttggttgc tgacaaatgt c. 21

<400> 29
ccttggtaaa cagtqagaat tattac 26

```
<400> 30
Met Ser Phe Tyr Ser Lys Gln Asp Tyr Asn Met Asp Leu Glu Leu Asp
  1           5           10          15
```

Glu Tyr Tyr Asn Lys Thr Leu Ala Thr Glu Asn Asn Thr Ala Ala Thr
20..... 25..... 30.....

Arg Asn Ser Asp Phe Pro Val Trp Asp Asp Tyr Lys Ser Ser Val Asp
35 40 45

Asp Leu Gln Tyr Phe Leu Ile Gly Leu Tyr Thr Phe Val Ser Leu Leu
50 55 60

Gly Phe Met Gly Asn Leu Leu Ile Leu Met Ala Leu Met Lys Lys Arg
65 70 75 80

Asn Gln Lys Thr Thr Val Asn Phe Leu Ile Gly Asn Leu Ala Phe Ser ...
85 90 95

Asp Ile Leu Val Val Leu Phe Cys Ser Pro Phe Thr Leu Thr Ser Val
100 105 110

Leu Leu Asp Gln Trp Met Phe Gly Lys Val Met Cys His Ile Met Pro
 115 120 125
 Phe Leu Gln Cys Val Ser Val Leu Val Ser Thr Leu Ile Leu Ile Ser
 130 135 140
 Ile Ala Ile Val Arg Tyr His Met Ile Lys His Pro Ile Ser Asn Asn
 145 150 155 160
 Leu Thr Ala Asn His Gly Tyr Phe Leu Ile Ala Thr Val Trp Thr Leu
 165 170 175
 Gly Phe Ala Ile Cys Ser Pro Leu Pro Val Phe His Ser Leu Val Glu
 180 185 190
 Leu Gln Glu Thr Phe Gly Ser Ala Leu Leu Ser Ser Arg Tyr Leu Cys
 195 200 205
 Val Glu Ser Trp Pro Ser Asp Ser Tyr Arg Ile Ala Phe Thr Ile Ser
 210 215 220
 Leu Leu Leu Val Gln Tyr Ile Leu Pro Leu Val Cys Leu Thr Val Ser
 225 230 235 240
 His Thr Ser Val Cys Arg Ser Ile Ser Cys Gly Leu Ser Asn Lys Glu
 245 250 255
 Asn Arg Leu Glu Glu Asn Glu Met Ile Asn Leu Thr Leu His Pro Ser
 260 265 270
 Arg Lys Ile Gly Pro Gln Val Lys Leu Ser Gly Ser His Lys Trp Ser
 275 280 285
 Tyr Ser Phe Ile Lys Lys His Arg Arg Arg Tyr Ser Lys Lys Thr Ala
 290 295 300
 Cys Val Leu Pro Ala Pro Glu Arg Pro Ser Gln Glu Asn His Ser Arg
 305 310 315 320
 Ile Leu Pro Glu Asn Phe Gly Ser Val Arg Ser Gln Leu Ser Ser Ser
 325 330 335
 Ser Lys Phe Ile Pro Gly Val Pro Thr Cys Phe Glu Ile Lys Pro Glu
 340 345 350
 Glu Asn Ser Asp Val His Glu Leu Arg Val Lys Arg Ser Val Thr Arg
 355 360 365
 Ile Lys Lys Arg Ser Arg Ser Val Phe Tyr Arg Leu Thr Ile Leu Ile
 370 375 380
 Leu Val Phe Ala Val Ser Trp Met Pro Leu His Leu Phe His Val Val
 385 390 395 400
 Thr Asp Phe Asn Asp Asn Leu Ile Ser Asn Arg His Phe Lys Leu Val
 405 410 415

Tyr Cys Ile Cys His Leu Leu Gly Met Met Ser Cys Cys Leu Asn Pro
 420 425 430

Ile Leu Tyr Gly Phe Leu Asn Asn Gly Ile Lys Ala Asp Leu Met Ser
 435 440 445

Leu Ile His Cys Leu His Met
 450 455

<210> 31

<211> 1406

<212> DNA

<213> Cercopithecus aethiops

<400> 31

```

ttttggttgc tgacaaatgt ctttttattc caagcaggac tataatatgg atttagagct 60
tgatgaatat tataacaaga cacttgccac agagaataat actgctgccca ctcggaattc 120
tgatttccca gtctgggatg actataaaaag cagtgtagat gacttacagt attttctgat 180
tgggctctat acatttgtaa gtcttcttgg ctttatgggg aatttactta ttttaatggc 240
tctcatgaaa aagcgtaatc agaagactac ggtaaacttc cttataggaa atctggcctt 300
ttctgacatc ttggttgtgc tgttttgcct acctttcaca ctgacgtctg tcttgctgga 360
tcagtggatg tttggcaaag tcatgtgcca tattatgcct tttctgcaat gtgtgtcagt 420
tttgggtttca actttaattt taatatcaat tgccattgtc aggtatcata tgataaaaaca 480
tcccactctc aataatttaa cagcaaacca tggctacttt ctgatatgta ctgtctggac 540
actagggttt gccatctgtt ctcctcttc agtgtttcac agtcttggg aacttcaaga 600
aacatttggg tcagcgttgc tgagcagcag gtatttatgt gttgagtcac ggccatctga 660
ttcatacaga attgccttta ctatctcttt attgctagtt cagtatatc tgcccttagt 720
ttgtcttact gtaagtcata caagtgtctg cagaagcata agctgtggat tgtccaacaa 780
agaaaacaga cttgaagaaa acgagatgat caacttaact cttcatccat ctagaaagat 840
tgggcctcag gtgaaactct ctggcagcca taaatggagt tattcattca tcaaaaaaca 900
cagaaggaga tatagcaaga agacagcatg tgtgttacct gctccagaaa gaccttctca 960
agagaaccac tccagaatac ttccagaaaa ctttggctct gtaagaagtc agctctcttc 1020
atccagtaag ttcataccag gggccccac ttgctttgaa ataaaacctg aagaaaattc 1080
agatgttcat gaattgagag taaaacgttc tgttacaaga ataaaaaaga gatctcgaag 1140
tgttttctac aggtgacca tactgatact agtatttgcg gttagtgtga tgccactaca 1200
ccttttccat gtggtaactg attttaatga caatcttatt tcaaataggc atttcaagtt 1260
ggtgtattgc atttgtcatt tgttgggcat gatgtcctgt tgtcttaatc caattctgta 1320
tggatttctt aataatggga ttaaagctga tttaatgtct cttatacact gtcttcatat 1380
gtaataattc tcaactgtta ccaagg 1406

```

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 August 2001 (02.08.2001)

PCT

(10) International Publication Number
WO 01/55103 A3

(51) International Patent Classification⁷: C07H 21/04,
C12P 21/06, C12N 15/63, 15/85, 15/86, C07K 5/100,
G01N 33/53

(21) International Application Number: PCT/US01/02804

(22) International Filing Date: 29 January 2001 (29.01.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/178,652 28 January 2000 (28.01.2000) US

(71) Applicant: NEUROGEN CORPORATION [US/US]; 35
Northeast Industrial Road, Branford, CT 06505 (US).

(72) Inventors: BENNETT, Michele; 35 NE Industrial Road,
Branford, CT 06505 (US). BRODBECK, Robbin; 35 NE
Industrial Road, Branford, CT 06505 (US). KRAUSE,
James; 35 NE Industrial Road, Branford, CT 06505 (US).

(74) Agents: RICHARDS, John; Ladas & Parry, 26 West 61st
Street, New York, NY 10023 et al. (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
13 December 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/55103 A3

(54) Title: CHIMERIC NEUROPEPTIDE Y RECEPTORS

(57) Abstract: Novel chimeric G-protein coupled receptors are provided as isolated polypeptides, membrane preparations containing such chimeric receptors, nucleic acids encoding such chimeric receptors, and cells expressing such receptors. The chimeric receptors are NPY5 receptors with most or all of either one or both of the third cytoplasmic loop domain or the C-terminal intracellular domain of NPY5 replaced with the corresponding region(s) of another NPY receptor, preferably an NPY1 receptor.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/02804

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07H 21/04; C12P 21/06; C12N 15/63; C12N 15/85; C12N 15/86; C07K 5/100; G01N 33/53;
US CL : 536/23.5; 536/23.4; 435/69.1; 435/320.1; 435/325; 530/350; 435/7.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 435/69.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| A | NAKAMURA et al. Identification of Two Isoforms of Mouse Neuropeptide Y-Y1 Receptor Generated by Alternative Splicing. J. Biol. Chem. December 1995, Vol 270. No. 50, pages 30102-30110, especially page 30105. | 1-9 |

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

| Special categories of cited documents: | |
|---|--|
| "A" document defining the general state of the art which is not considered to be of particular relevance | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| "E" earlier application or patent published on or after the international filing date | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "O" document referring to an oral disclosure, use, exhibition or other means | "&" document member of the same patent family |
| "P" document published prior to the international filing date but later than the priority date claimed | |

Date of the actual completion of the international search

12 June 2001 (12.06.2001)

Date of mailing of the international search report

26 JUL 2001

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Sandra Wegert

Telephone No. 703.308.1600

TERRY J. DEY
PARALEGAL SPECIALIST
TECHNOLOGY CENTER 1600

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/02804

Continuation of B. **FIELDS SEARCHED** Item3: Databases: MEDLINE, BIOSIS, USPAT, EPO, DERWENT. Search Terms: NPY receptor chimera*, Y1, Y5, Y1/Y5, Y5/Y1, NPY5, NPY1, Neuropeptide Y receptor, *Y-Y1 receptor, sf9, Autographa californica, frugiperda, GTP*S, anorectic, anxiolytic, human, sapiens. Bennet M, Richards J, Brodbeck R, Krause J. Electronic (sequence) databases: SPTREMBL_15, GenEmbl, EST, PIR_66, SwissProt_39, Issued_Patents_NA, A_Geneseq_36, Issued_Patents_AA, Pending_Patents_NA.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 August 2001 (02.08.2001)

PCT

(10) International Publication Number
WO 01/55103 A3

(51) International Patent Classification⁷: C07H 21/04,
C12P 21/06, C12N 15/63, 15/85, 15/86, C07K 5/100,
G01N 33/53

(21) International Application Number: PCT/US01/02804

(22) International Filing Date: 29 January 2001 (29.01.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/178,652 28 January 2000 (28.01.2000) US

(71) Applicant: **NEUROGEN CORPORATION** [US/US]; 35
Northeast Industrial Road, Branford, CT 06505 (US).

(72) Inventors: **BENNETT, Michele**; 35 NE Industrial Road,
Branford, CT 06505 (US). **BRODBECK, Robbin**; 35 NE
Industrial Road, Branford, CT 06505 (US). **KRAUSE,**
James; 35 NE Industrial Road, Branford, CT 06505 (US).

(74) Agents: **RICHARDS, John**; Ladas & Parry, 26 West 61st
Street, New York, NY 10023 et al. (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
13 December 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CHIMERIC NEUROPEPTIDE Y RECEPTORS

(57) Abstract: Novel chimeric G-protein coupled receptors are provided as isolated polypeptides, membrane preparations containing such chimeric receptors, nucleic acids encoding such chimeric receptors, and cells expressing such receptors. The chimeric receptors are NPY5 receptors with most or all of either one or both of the third cytoplasmic loop domain or the C-terminal intracellular domain of NPY5 replaced with the corresponding region(s) of another NPY receptor, preferably an NPY1 receptor.

WO 01/55103 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/02804

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07H 21/04; C12P 21/06; C12N 15/63; C12N 15/85; C12N 15/86; C07K 5/100; G01N 33/53;
US CL : 536/23.5; 536/23.4; 435/69.1; 435/320.1; 435/325; 530/350; 435/7.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 435/69.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| A | NAKAMURA et al. Identification of Two Isoforms of Mouse Neuropeptide Y-Y1 Receptor Generated by Alternative Splicing. J. Biol. Chem. December 1995, Vol 270. No. 50, pages 30102-30110, especially page 30105. | 1-9 |

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

| Special categories of cited documents: | |
|---|--|
| * "A" document defining the general state of the art which is not considered to be of particular relevance | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| * "E" earlier application or patent published on or after the international filing date | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| * "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| * "O" document referring to an oral disclosure, use, exhibition or other means | "&" document member of the same patent family |
| * "P" document published prior to the international filing date but later than the priority date claimed | |

Date of the actual completion of the international search

12 June 2001 (12.06.2001)

Date of mailing of the international search report

26 JUL 2001

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Sandra Wegert

Telephone No. 703.308.7000

TERRY J. DEY
PARALEGAL SPECIALIST
TECHNOLOGY CENTER 1600

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/02804

Continuation of B. **FIELDS SEARCHED** Item3: Databases: MEDLINE, BIOSIS, USPAT, EPO, DERWENT. Search Terms: NPY receptor chimera*, Y1, Y5, Y1/Y5, Y5/Y1, NPYS, NPY1, Neuropeptide Y receptor, *Y-Y1 receptor, sf9, Autographa californica, frugiperda, GTP*S, anorectic, anxiolytic, human, sapiens. Bennet M, Richards J, Brodbeck R, Krause J. Electronic (sequence) databases: SPTREMBL_15, GenEmbl, EST, PIR_66, SwissProt_39, Issued_Patents_NA, A_Geneseq_36, Issued_Patents_AA, Pending_Patents_NA.